{"id":"pd1","name":"PD-1","symbol":"PDCD1","route":"/targets/pd1/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8760","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000188389","uniprot":"https://www.uniprot.org/uniprotkb/Q15116/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q15116","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3307223","open-targets":"https://platform.opentargets.org/target/ENSG00000188389","civic":"https://civicdb.org/genes/5133/summary","oncokb":"https://www.oncokb.org/gene/PDCD1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PDCD1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=PDCD1","depmap":"https://depmap.org/portal/gene/PDCD1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000188389-PDCD1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/5133","omim":"https://www.omim.org/entry/600244"}],"products":[{"id":"ai-081","name":"AI-081","status":"phase-2","modality":"bispecific antibody","route":"/drugs/ai-081/"},{"id":"azd7789","name":"AZD7789","status":"phase-2","modality":"bispecific antibody","route":"/drugs/azd7789/"},{"id":"balstilimab","name":"Balstilimab","status":"phase-2","modality":"Monoclonal antibody","route":"/drugs/balstilimab/"},{"id":"bcd-217","name":"BCD-217","status":"phase-3","modality":"antibody combination (nurulimab and prolgolimab; INN stem -mab; form not stated in the registry record)","route":"/drugs/bcd-217/"},{"id":"cadonilimab","name":"Cadonilimab","status":"approved","modality":"Bispecific antibody (PD-1×CTLA-4)","route":"/drugs/cadonilimab/"},{"id":"camrelizumab","name":"Camrelizumab","status":"approved","modality":"Monoclonal antibody (anti-PD-1)","route":"/drugs/camrelizumab/"},{"id":"camrelizumab-rivoceranib","name":"Camrelizumab + rivoceranib","status":"approved","modality":"PD-1 antibody + oral VEGFR2 inhibitor","route":"/drugs/camrelizumab-rivoceranib/"},{"id":"cemiplimab","name":"Cemiplimab","status":"approved","modality":"Monoclonal antibody (anti-PD-1)","route":"/drugs/cemiplimab/"},{"id":"dostarlimab","name":"Dostarlimab","status":"approved","modality":"Monoclonal antibody (anti-PD-1)","route":"/drugs/dostarlimab/"},{"id":"gc101-til","name":"GC101 TIL","status":"phase-2","modality":"TIL therapy","route":"/drugs/gc101-til/"},{"id":"ibi363","name":"IBI363","status":"phase-2","modality":"fusion protein","route":"/drugs/ibi363/"},{"id":"ivonescimab","name":"Ivonescimab","status":"approved","modality":"Bispecific antibody (PD-1×VEGF)","route":"/drugs/ivonescimab/"},{"id":"lb1410","name":"LB1410","status":"phase-2","modality":"bispecific antibody","route":"/drugs/lb1410/"},{"id":"lorigerlimab","name":"Lorigerlimab","status":"phase-2","modality":"bispecific antibody","route":"/drugs/lorigerlimab/"},{"id":"nivolumab","name":"Nivolumab","status":"approved","modality":"Monoclonal antibody (anti-PD-1)","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","name":"Pembrolizumab","status":"approved","modality":"Monoclonal antibody (anti-PD-1)","route":"/drugs/pembrolizumab/"},{"id":"penpulimab","name":"Penpulimab","status":"approved","modality":"Anti-PD-1 monoclonal antibody (IgG1, Fc-engineered null)","route":"/drugs/penpulimab/"},{"id":"pucotenlimab","name":"Pucotenlimab","status":"approved","modality":"Anti-PD-1 monoclonal antibody, intravenous","route":"/drugs/pucotenlimab/"},{"id":"relatlimab-nivolumab","name":"Relatlimab + nivolumab","status":"approved","modality":"Fixed-dose bispecific combination (anti-LAG-3 + anti-PD-1)","route":"/drugs/relatlimab-nivolumab/"},{"id":"retifanlimab","name":"Retifanlimab","status":"approved","modality":"Anti-PD-1 monoclonal antibody (IgG4)","route":"/drugs/retifanlimab/"},{"id":"rilvegostomig","name":"Rilvegostomig","status":"phase-2","modality":"bispecific antibody","route":"/drugs/rilvegostomig/"},{"id":"sasanlimab","name":"Sasanlimab","status":"phase-3","modality":"monoclonal antibody","route":"/drugs/sasanlimab/"},{"id":"serplulimab","name":"Serplulimab","status":"approved","modality":"Monoclonal antibody (anti-PD-1)","route":"/drugs/serplulimab/"},{"id":"sintilimab","name":"Sintilimab","status":"approved","modality":"Monoclonal antibody (anti-PD-1, IgG4)","route":"/drugs/sintilimab/"},{"id":"ssgj-705","name":"SSGJ-705","status":"phase-2","modality":"monoclonal antibody","route":"/drugs/ssgj-705/"},{"id":"ssgj-706","name":"SSGJ-706","status":"phase-2","modality":"bispecific antibody","route":"/drugs/ssgj-706/"},{"id":"t3011","name":"T3011","status":"phase-2","modality":"oncolytic virus (intratumoral oncolytic HSV-1, per the sponsor's pipeline page; registered as a drug on ClinicalTrials.gov)","route":"/drugs/t3011/"},{"id":"tak-928","name":"TAK-928","status":"phase-3","modality":"bispecific antibody","route":"/drugs/tak-928/"},{"id":"tislelizumab","name":"Tislelizumab","status":"approved","modality":"Monoclonal antibody (anti-PD-1)","route":"/drugs/tislelizumab/"},{"id":"toripalimab","name":"Toripalimab","status":"approved","modality":"Monoclonal antibody (anti-PD-1)","route":"/drugs/toripalimab/"},{"id":"tqb2450","name":"TQB2450","status":"phase-3","modality":"monoclonal antibody","route":"/drugs/tqb2450/"},{"id":"zimberelimab","name":"Zimberelimab","status":"approved","modality":"Anti-PD-1 monoclonal antibody, intravenous","route":"/drugs/zimberelimab/"}],"trials":[{"id":"nct05625399","name":"A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma","nct":"NCT05625399","phase":"3","status":"active"},{"id":"nct04810078","name":"A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance","nct":"NCT04810078","phase":"3","status":"active"},{"id":"nct04379635","name":"Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)","nct":"NCT04379635","phase":"3","status":"active"},{"id":"fianlimab-phase3-melanoma","name":"Fianlimab + cemiplimab phase 3 (first-line melanoma)","nct":"NCT05352672","phase":"3","status":"negative"},{"id":"harmoni-3","name":"HARMONi-3","nct":"NCT05899608","phase":"3","status":"mixed"},{"id":"herizon-gea-01","name":"HERIZON-GEA-01","nct":"NCT05152147","phase":"3","status":"positive"},{"id":"interpath-001","name":"INTerpath-001 (V940-001)","nct":"NCT05933577","phase":"3","status":"positive"},{"id":"litespark-012","name":"LITESPARK-012","nct":"NCT04736706","phase":"3","status":"negative"},{"id":"litespark-022","name":"LITESPARK-022","nct":"NCT05239728","phase":"3","status":"positive"},{"id":"nct03602859","name":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer","nct":"NCT03602859","phase":"3","status":"active"},{"id":"nct05722015","name":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)","nct":"NCT05722015","phase":"3","status":"active"},{"id":"nct06212752","name":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension","nct":"NCT06212752","phase":"3","status":"active"},{"id":"ascent-04","name":"ASCENT-04 / KEYNOTE-D19","nct":"NCT05382286","phase":"3","status":"positive"},{"id":"c-post","name":"C-POST (cemiplimab after surgery and radiotherapy for high-risk skin squamous cell carcinoma)","nct":"NCT03969004","phase":"3","status":"positive"},{"id":"ev-303","name":"EV-303 / KEYNOTE-905","nct":"NCT03924895","phase":"3","status":"positive"},{"id":"ev-304","name":"EV-304 / KEYNOTE-B15","nct":"NCT04700124","phase":"3","status":"positive"},{"id":"keynote-641","name":"KEYNOTE-641","nct":"NCT03834493","phase":"3","status":"negative"},{"id":"keynote-689","name":"KEYNOTE-689","nct":"NCT03765918","phase":"3","status":"positive"},{"id":"keynote-921","name":"KEYNOTE-921","nct":"NCT03834506","phase":"3","status":"negative"},{"id":"keynote-991","name":"KEYNOTE-991","nct":"NCT04191096","phase":"3","status":"negative"},{"id":"keynote-b96","name":"KEYNOTE-B96 / ENGOT-ov65","nct":"NCT05116189","phase":"3","status":"positive"},{"id":"nivopostop","name":"NIVOPOSTOP (GORTEC 2018-01)","nct":"NCT03576417","phase":"3","status":"positive"},{"id":"nct05224141","name":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","nct":"NCT05224141","phase":"3","status":"active"},{"id":"pod1um-303","name":"POD1UM-303/InterAACT-2","nct":"NCT04472429","phase":"3","status":"positive"},{"id":"relativity-098","name":"RELATIVITY-098","nct":"NCT05002569","phase":"3","status":"negative"},{"id":"nct03036098","name":"Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer","nct":"NCT03036098","phase":"3","status":"active"},{"id":"nct04025879","name":"A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer","nct":"NCT04025879","phase":"3","status":"active"},{"id":"checkmate-8hw","name":"CheckMate 8HW","nct":"NCT04008030","phase":"3","status":"positive"},{"id":"checkmate-9dw","name":"CheckMate 9DW","nct":"NCT04039607","phase":"3","status":"positive"},{"id":"compassion-16","name":"COMPASSION-16 / AK104-303","nct":"NCT04982237","phase":"3","status":"positive"},{"id":"continuum","name":"CONTINUUM","nct":"NCT03700476","phase":"3","status":"positive"},{"id":"harmoni-2","name":"HARMONi-2","nct":"NCT05499390","phase":"3","status":"positive"},{"id":"harmoni-a","name":"HARMONi-A","nct":"NCT05184712","phase":"3","status":"positive"},{"id":"leap-012","name":"LEAP-012","nct":"NCT04246177","phase":"3","status":"mixed"},{"id":"nadina","name":"NADINA","nct":"NCT04949113","phase":"3","status":"positive"},{"id":"neotorch","name":"Neotorch","nct":"NCT04158440","phase":"3","status":"positive"},{"id":"nct04956692","name":"Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan","nct":"NCT04956692","phase":"3","status":"active"},{"id":"tinivo-2","name":"TiNivo-2","nct":"NCT04987203","phase":"3","status":"negative"},{"id":"cares-310","name":"CARES-310","nct":"NCT03764293","phase":"3","status":"positive"},{"id":"checkmate-498","name":"CheckMate 498","nct":"NCT02617589","phase":"3","status":"negative"},{"id":"ev-302","name":"EV-302 / KEYNOTE-A39","nct":"NCT04223856","phase":"3","status":"positive"},{"id":"keynote-671","name":"KEYNOTE-671","nct":"NCT03425643","phase":"3","status":"positive"},{"id":"keynote-859","name":"KEYNOTE-859","nct":"NCT03675737","phase":"3","status":"positive"},{"id":"keynote-966","name":"KEYNOTE-966","nct":"NCT04003636","phase":"3","status":"positive"},{"id":"keynote-a18","name":"KEYNOTE-A18 / ENGOT-cx11 / GOG-3047","nct":"NCT04221945","phase":"3","status":"positive"},{"id":"low-dose-nivolumab-tmh","name":"Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial)","phase":"3","status":"positive"},{"id":"nrg-gy018-keynote-868","name":"NRG-GY018 / KEYNOTE-868","nct":"NCT03914612","phase":"3","status":"positive"},{"id":"orient-16","name":"ORIENT-16","nct":"NCT03745170","phase":"3","status":"positive"},{"id":"ruby","name":"RUBY / ENGOT-EN6 / GOG-3031","nct":"NCT03981796","phase":"3","status":"positive"},{"id":"swog-s1826","name":"SWOG S1826","nct":"NCT03907488","phase":"3","status":"positive"},{"id":"nct03635983","name":"A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma","nct":"NCT03635983","phase":"3","status":"completed"},{"id":"astrum-005","name":"ASTRUM-005","nct":"NCT04063163","phase":"3","status":"positive"},{"id":"checkmate-548","name":"CheckMate 548","nct":"NCT02667587","phase":"3","status":"negative"},{"id":"checkmate-816","name":"CheckMate 816","nct":"NCT02998528","phase":"3","status":"positive"},{"id":"checkmate-915","name":"CheckMate 915","nct":"NCT03068455","phase":"3","status":"negative"},{"id":"cosmic-313","name":"COSMIC-313","nct":"NCT03937219","phase":"3","status":"mixed"},{"id":"jupiter-06","name":"JUPITER-06","nct":"NCT03829969","phase":"3","status":"positive"},{"id":"keynote-091","name":"KEYNOTE-091 (PEARLS)","nct":"NCT02504372","phase":"3","status":"mixed"},{"id":"keynote-412","name":"KEYNOTE-412","nct":"NCT03040999","phase":"3","status":"negative"},{"id":"leap-002","name":"LEAP-002","nct":"NCT03713593","phase":"3","status":"negative"},{"id":"nct02263508","name":"Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma","nct":"NCT02263508","phase":"3"},{"id":"rationale-302","name":"RATIONALE-302","nct":"NCT03430843","phase":"3","status":"positive"},{"id":"rationale-306","name":"RATIONALE-306","nct":"NCT03783442","phase":"3","status":"positive"},{"id":"camel","name":"CameL","nct":"NCT03134872","phase":"3","status":"positive"},{"id":"captain-1st","name":"CAPTAIN-1st","nct":"NCT03707509","phase":"3","status":"positive"},{"id":"checkmate-274","name":"CheckMate 274","nct":"NCT02632409","phase":"3","status":"positive"},{"id":"checkmate-577","name":"CheckMate 577","nct":"NCT02743494","phase":"3","status":"mixed"},{"id":"checkmate-648","name":"CheckMate 648","nct":"NCT03143153","phase":"3","status":"positive"},{"id":"clear","name":"CLEAR (KEYNOTE-581)","nct":"NCT02811861","phase":"3","status":"positive"},{"id":"dreamseq","name":"DREAMseq (ECOG-ACRIN EA6134)","nct":"NCT02224781","phase":"3","status":"positive"},{"id":"empower-cervical-1","name":"EMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9","nct":"NCT03257267","phase":"3","status":"positive"},{"id":"empower-lung-1","name":"EMPOWER-Lung 1","nct":"NCT03088540","phase":"3","status":"positive"},{"id":"escort-1st","name":"ESCORT-1st","nct":"NCT03691090","phase":"3","status":"positive"},{"id":"jupiter-02","name":"JUPITER-02","nct":"NCT03581786","phase":"3","status":"positive"},{"id":"keynote-119","name":"KEYNOTE-119","nct":"NCT02555657","phase":"3","status":"negative"},{"id":"keynote-564","name":"KEYNOTE-564","nct":"NCT03142334","phase":"3","status":"positive"},{"id":"keynote-716","name":"KEYNOTE-716","nct":"NCT03553836","phase":"3","status":"positive"},{"id":"keynote-775","name":"KEYNOTE-775 / Study 309","nct":"NCT03517449","phase":"3","status":"positive"},{"id":"keynote-811","name":"KEYNOTE-811","nct":"NCT03615326","phase":"3","status":"positive"},{"id":"keynote-826","name":"KEYNOTE-826","nct":"NCT03635567","phase":"3","status":"positive"},{"id":"lung-map-s1400i","name":"Lung-MAP S1400I: nivolumab with or without ipilimumab","nct":"NCT02785952","phase":"3","status":"negative"},{"id":"checkmate-143","name":"CheckMate 143","nct":"NCT02017717","phase":"3","status":"negative"},{"id":"checkmate-649","name":"CheckMate 649","nct":"NCT02872116","phase":"3","status":"positive"},{"id":"checkmate-743","name":"CheckMate 743","nct":"NCT02899299","phase":"3","status":"positive"},{"id":"checkmate-9er","name":"CheckMate 9ER","nct":"NCT03141177","phase":"3","status":"positive"},{"id":"checkmate-9la","name":"CheckMate 9LA","nct":"NCT03215706","phase":"3","status":"positive"},{"id":"impassion131","name":"IMpassion131","nct":"NCT03125902","phase":"3","status":"negative"},{"id":"keynote-062","name":"KEYNOTE-062","nct":"NCT02494583","phase":"3","status":"mixed"},{"id":"keynote-177","name":"KEYNOTE-177","nct":"NCT02563002","phase":"3","status":"positive"},{"id":"keynote-204","name":"KEYNOTE-204","nct":"NCT02684292","phase":"3","status":"positive"},{"id":"keynote-355","name":"KEYNOTE-355","nct":"NCT02819518","phase":"3","status":"positive"},{"id":"keynote-522","name":"KEYNOTE-522","nct":"NCT03036488","phase":"3","status":"positive"},{"id":"keynote-590","name":"KEYNOTE-590","nct":"NCT03189719","phase":"3","status":"positive"},{"id":"orient-11","name":"ORIENT-11","nct":"NCT03607539","phase":"3","status":"positive"},{"id":"checkmate-227","name":"CheckMate 227","nct":"NCT02477826","phase":"3","status":"positive"},{"id":"imblaze370","name":"IMblaze370","nct":"NCT02788279","phase":"3","status":"negative"},{"id":"keynote-042","name":"KEYNOTE-042","nct":"NCT02220894","phase":"3","status":"positive"},{"id":"keynote-048","name":"KEYNOTE-048","nct":"NCT02358031","phase":"3","status":"positive"},{"id":"keynote-426","name":"KEYNOTE-426","nct":"NCT02853331","phase":"3","status":"positive"},{"id":"nct03260894","name":"Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)","nct":"NCT03260894","phase":"3","status":"completed"},{"id":"nct03358472","name":"Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)","nct":"NCT03358472","phase":"3","status":"completed"},{"id":"nct02362594","name":"Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)","nct":"NCT02362594","phase":"3","status":"active"},{"id":"checkmate-214","name":"CheckMate 214","nct":"NCT02231749","phase":"3","status":"positive"},{"id":"keynote-407","name":"KEYNOTE-407","nct":"NCT02775435","phase":"3","status":"positive"},{"id":"attraction-2","name":"ATTRACTION-2","nct":"NCT02267343","phase":"3","status":"positive"},{"id":"checkmate-026","name":"CheckMate 026","nct":"NCT02041533","phase":"3","status":"negative"},{"id":"checkmate-238","name":"CheckMate 238","nct":"NCT02388906","phase":"3","status":"positive"},{"id":"checkmate-141","name":"CheckMate 141","nct":"NCT02105636","phase":"3","status":"positive"},{"id":"keynote-024-189","name":"KEYNOTE-024 & KEYNOTE-189","nct":"NCT02142738","phase":"3","status":"positive"},{"id":"checkmate-017","name":"CheckMate 017","nct":"NCT01642004","phase":"3","status":"positive"},{"id":"checkmate-025","name":"CheckMate 025","nct":"NCT01668784","phase":"3","status":"positive"},{"id":"checkmate-057","name":"CheckMate 057","nct":"NCT01673867","phase":"3","status":"positive"},{"id":"checkmate-067","name":"CheckMate 067","nct":"NCT01844505","phase":"3","status":"positive"},{"id":"keynote-006","name":"KEYNOTE-006","nct":"NCT01866319","phase":"3","status":"positive"},{"id":"nct06592326","name":"9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer","nct":"NCT06592326","phase":"3","status":"recruiting"},{"id":"nct05732805","name":"A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma","nct":"NCT05732805","phase":"3","status":"active"},{"id":"nct06698042","name":"A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)","nct":"NCT06698042","phase":"3","status":"active"},{"id":"nct07216703","name":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc","nct":"NCT07216703","phase":"3","status":"recruiting"},{"id":"nct06966700","name":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","nct":"NCT06966700","phase":"3","status":"recruiting"},{"id":"nct06931717","name":"A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Re","nct":"NCT06931717","phase":"3","status":"recruiting"},{"id":"nct07113275","name":"A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course R","nct":"NCT07113275","phase":"3","status":"recruiting"},{"id":"nct05890742","name":"A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer","nct":"NCT05890742","phase":"3","status":"active"},{"id":"nct07111832","name":"A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer","nct":"NCT07111832","phase":"3","status":"recruiting"},{"id":"nct04657991","name":"A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma","nct":"NCT04657991","phase":"3","status":"active"},{"id":"nct06868277","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer","nct":"NCT06868277","phase":"3","status":"recruiting"},{"id":"nct06627647","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N","nct":"NCT06627647","phase":"3","status":"recruiting"},{"id":"nct06692738","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s","nct":"NCT06692738","phase":"3","status":"recruiting"},{"id":"nct05984277","name":"A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung","nct":"NCT05984277","phase":"3","status":"active"},{"id":"nct07833202","name":"A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutatio","nct":"NCT07833202","phase":"3","status":"planned"},{"id":"nct07023315","name":"A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma","nct":"NCT07023315","phase":"3","status":"recruiting"},{"id":"nct06112379","name":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","nct":"NCT06112379","phase":"3","status":"active"},{"id":"nct05489289","name":"A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection","nct":"NCT05489289","phase":"3","status":"recruiting"},{"id":"nct06953999","name":"A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer","nct":"NCT06953999","phase":"3","status":"recruiting"},{"id":"nct06764875","name":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","nct":"NCT06764875","phase":"3","status":"recruiting"},{"id":"nct06908304","name":"A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC","nct":"NCT06908304","phase":"3","status":"recruiting"},{"id":"nct06564844","name":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C","nct":"NCT06564844","phase":"3","status":"active"},{"id":"nct07336953","name":"A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic P","nct":"NCT07336953","phase":"3","status":"planned"},{"id":"nct06048315","name":"A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs W","nct":"NCT06048315","phase":"3","status":"planned"},{"id":"nct07502300","name":"A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Pa","nct":"NCT07502300","phase":"3","status":"recruiting"},{"id":"nct07802821","name":"A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Sm","nct":"NCT07802821","phase":"3","status":"planned"},{"id":"nct07217301","name":"A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer","nct":"NCT07217301","phase":"3","status":"recruiting"},{"id":"nct07822542","name":"A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Pat","nct":"NCT07822542","phase":"3","status":"planned"},{"id":"nct05920356","name":"A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi","nct":"NCT05920356","phase":"3","status":"recruiting"},{"id":"nct06793215","name":"A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip","nct":"NCT06793215","phase":"3","status":"recruiting"},{"id":"nct06875310","name":"A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)","nct":"NCT06875310","phase":"3","status":"recruiting"},{"id":"nct06617416","name":"A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC","nct":"NCT06617416","phase":"3","status":"recruiting"},{"id":"nct05235516","name":"A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer","nct":"NCT05235516","phase":"3","status":"active"},{"id":"nct05990127","name":"A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer","nct":"NCT05990127","phase":"3","status":"planned"},{"id":"nct06371157","name":"A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepat","nct":"NCT06371157","phase":"3","status":"recruiting"},{"id":"nct07010263","name":"A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor","nct":"NCT07010263","phase":"3","status":"recruiting"},{"id":"nct07276399","name":"A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer","nct":"NCT07276399","phase":"3","status":"recruiting"},{"id":"nct06699212","name":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of ","nct":"NCT06699212","phase":"3","status":"recruiting"},{"id":"nct06472076","name":"A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)","nct":"NCT06472076","phase":"3","status":"active"},{"id":"nct03729245","name":"A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)","nct":"NCT03729245","phase":"3"},{"id":"nct07178795","name":"A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC","nct":"NCT07178795","phase":"3","status":"recruiting"},{"id":"nct05999149","name":"A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BC","nct":"NCT05999149","phase":"3","status":"recruiting"},{"id":"nct07315750","name":"A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.","nct":"NCT07315750","phase":"3","status":"recruiting"},{"id":"nct06256588","name":"A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma","nct":"NCT06256588","phase":"3","status":"recruiting"},{"id":"nct06119581","name":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer","nct":"NCT06119581","phase":"3","status":"recruiting"},{"id":"nct05798819","name":"A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervic","nct":"NCT05798819","phase":"3","status":"recruiting"},{"id":"nct05652894","name":"A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer","nct":"NCT05652894","phase":"3","status":"active"},{"id":"nct06077760","name":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (","nct":"NCT06077760","phase":"3","status":"active"},{"id":"nct06976190","name":"A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcin","nct":"NCT06976190","phase":"3","status":"recruiting"},{"id":"nct05751928","name":"A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma","nct":"NCT05751928","phase":"3","status":"active"},{"id":"nct03873402","name":"A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer","nct":"NCT03873402","phase":"3","status":"active"},{"id":"nct03383458","name":"A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation","nct":"NCT03383458","phase":"3","status":"active"},{"id":"nct05899049","name":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study","nct":"NCT05899049","phase":"3","status":"active"},{"id":"nct06623422","name":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","nct":"NCT06623422","phase":"3","status":"recruiting"},{"id":"nct04974398","name":"A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma","nct":"NCT04974398","phase":"3","status":"active"},{"id":"nct05302284","name":"A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma","nct":"NCT05302284","phase":"3","status":"recruiting"},{"id":"nct07221253","name":"A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)","nct":"NCT07221253","phase":"3","status":"recruiting"},{"id":"nct06312176","name":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","nct":"NCT06312176","phase":"3","status":"recruiting"},{"id":"nct06841354","name":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","nct":"NCT06841354","phase":"3","status":"recruiting"},{"id":"nct04165317","name":"A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer","nct":"NCT04165317","phase":"3","status":"active"},{"id":"nct06711900","name":"A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative P","nct":"NCT06711900","phase":"3","status":"active"},{"id":"nct06448312","name":"A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","nct":"NCT06448312","phase":"3","status":"active"},{"id":"nct07672223","name":"A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)","nct":"NCT07672223","phase":"3","status":"planned"},{"id":"nct05320692","name":"A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma","nct":"NCT05320692","phase":"3","status":"active"},{"id":"nct07740720","name":"A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer","nct":"NCT07740720","phase":"3","status":"planned"},{"id":"nct04523272","name":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer","nct":"NCT04523272","phase":"3","status":"active"},{"id":"nct07679360","name":"A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer","nct":"NCT07679360","phase":"3","status":"recruiting"},{"id":"nct06497985","name":"A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients","nct":"NCT06497985","phase":"3","status":"recruiting"},{"id":"nct06901531","name":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","nct":"NCT06901531","phase":"3","status":"recruiting"},{"id":"nct06312137","name":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm","nct":"NCT06312137","phase":"3","status":"recruiting"},{"id":"nct07756645","name":"A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advan","nct":"NCT07756645","phase":"3","status":"planned"},{"id":"nct06311721","name":"A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer","nct":"NCT06311721","phase":"3","status":"active"},{"id":"nct06939595","name":"A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer","nct":"NCT06939595","phase":"3","status":"active"},{"id":"nct06952504","name":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan","nct":"NCT06952504","phase":"3","status":"recruiting"},{"id":"nct06022861","name":"A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma","nct":"NCT06022861","phase":"3","status":"recruiting"},{"id":"nct06561386","name":"A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N","nct":"NCT06561386","phase":"3","status":"recruiting"},{"id":"nct06348199","name":"A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-s","nct":"NCT06348199","phase":"3","status":"active"},{"id":"nct06054555","name":"A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma","nct":"NCT06054555","phase":"3","status":"active"},{"id":"nct04639180","name":"A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recur","nct":"NCT04639180","phase":"3","status":"active"},{"id":"nct04170283","name":"A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib","nct":"NCT04170283","phase":"3","status":"active"},{"id":"nct07541170","name":"A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese","nct":"NCT07541170","phase":"3","status":"recruiting"},{"id":"nct05353257","name":"A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage","nct":"NCT05353257","phase":"3","status":"active"},{"id":"nct07361510","name":"A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P","nct":"NCT07361510","phase":"3","status":"recruiting"},{"id":"nct07286266","name":"A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","nct":"NCT07286266","phase":"3","status":"recruiting"},{"id":"nct05048797","name":"A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic N","nct":"NCT05048797","phase":"3","status":"active"},{"id":"nct06452277","name":"A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-sma","nct":"NCT06452277","phase":"3","status":"recruiting"},{"id":"nct06246916","name":"A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)","nct":"NCT06246916","phase":"3","status":"recruiting"},{"id":"nct06545955","name":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","nct":"NCT06545955","phase":"3","status":"recruiting"},{"id":"nct05608291","name":"A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back Af","nct":"NCT05608291","phase":"3","status":"active"},{"id":"nct07715396","name":"Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden","nct":"NCT07715396","phase":"3","status":"planned"},{"id":"nct06520683","name":"Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer","nct":"NCT06520683","phase":"3","status":"recruiting"},{"id":"nct04772287","name":"Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)","nct":"NCT04772287","phase":"3","status":"planned"},{"id":"ahod2131","name":"AHOD2131 (COG / NCTN)","nct":"NCT05675410","phase":"3","status":"recruiting"},{"id":"nct05840016","name":"AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","nct":"NCT05840016","phase":"3","status":"active"},{"id":"nct06767527","name":"AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer","nct":"NCT06767527","phase":"3","status":"recruiting"},{"id":"nct07720284","name":"An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC","nct":"NCT07720284","phase":"3","status":"recruiting"},{"id":"nct05862337","name":"Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.","nct":"NCT05862337","phase":"3","status":"recruiting"},{"id":"nct07686796","name":"Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A P","nct":"NCT07686796","phase":"3","status":"planned"},{"id":"ascent-05","name":"ASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63)","nct":"NCT05633654","phase":"3","status":"recruiting"},{"id":"nct06151574","name":"Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment","nct":"NCT06151574","phase":"3","status":"active"},{"id":"nct07195695","name":"Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati","nct":"NCT07195695","phase":"3","status":"recruiting"},{"id":"nct05317858","name":"Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets","nct":"NCT05317858","phase":"3","status":"recruiting"},{"id":"nct06566755","name":"Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer","nct":"NCT06566755","phase":"3","status":"recruiting"},{"id":"nct04906993","name":"Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer","nct":"NCT04906993","phase":"3","status":"active"},{"id":"nct06096844","name":"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial","nct":"NCT06096844","phase":"3","status":"recruiting"},{"id":"nct06767514","name":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1","nct":"NCT06767514","phase":"3","status":"recruiting"},{"id":"nct06640530","name":"Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin","nct":"NCT06640530","phase":"3","status":"active"},{"id":"nct06745908","name":"Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In","nct":"NCT06745908","phase":"3","status":"recruiting"},{"id":"nct05171660","name":"Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer","nct":"NCT05171660","phase":"3","status":"active"},{"id":"nct06632327","name":"Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer","nct":"NCT06632327","phase":"3","status":"active"},{"id":"nct04339218","name":"Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma","nct":"NCT04339218","phase":"3","status":"recruiting"},{"id":"nct05555732","name":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","nct":"NCT05555732","phase":"3","status":"active"},{"id":"nct06989112","name":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC","nct":"NCT06989112","phase":"3","status":"recruiting"},{"id":"nct05911295","name":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2","nct":"NCT05911295","phase":"3","status":"active"},{"id":"nct06556563","name":"EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma","nct":"NCT06556563","phase":"3","status":"recruiting"},{"id":"nct04099251","name":"Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma","nct":"NCT04099251","phase":"3","status":"active"},{"id":"nct05055908","name":"Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors","nct":"NCT05055908","phase":"3","status":"recruiting"},{"id":"nct03711032","name":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)","nct":"NCT03711032","phase":"3","status":"active"},{"id":"nct04241185","name":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)","nct":"NCT04241185","phase":"3","status":"active"},{"id":"nct07566156","name":"Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)","nct":"NCT07566156","phase":"3","status":"recruiting"},{"id":"nct07405164","name":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","nct":"NCT07405164","phase":"3","status":"recruiting"},{"id":"nct05760378","name":"Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.","nct":"NCT05760378","phase":"3","status":"recruiting"},{"id":"nct07815834","name":"FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02)","nct":"NCT07815834","phase":"3","status":"planned"},{"id":"nct07710885","name":"Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer","nct":"NCT07710885","phase":"3","status":"recruiting"},{"id":"nct07722494","name":"IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer","nct":"NCT07722494","phase":"3","status":"recruiting"},{"id":"nct06928389","name":"Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer","nct":"NCT06928389","phase":"3","status":"recruiting"},{"id":"nct06505837","name":"JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）","nct":"NCT06505837","phase":"3","status":"active"},{"id":"liger-hn1","name":"LiGeR-HN1","nct":"NCT06525220","phase":"3","status":"recruiting"},{"id":"nct07620574","name":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study","nct":"NCT07620574","phase":"3","status":"recruiting"},{"id":"nct06216301","name":"LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC","nct":"NCT06216301","phase":"3","status":"recruiting"},{"id":"nct06097728","name":"MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma","nct":"NCT06097728","phase":"3","status":"active"},{"id":"nct06081244","name":"NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)","nct":"NCT06081244","phase":"3","status":"recruiting"},{"id":"nct05116462","name":"Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer","nct":"NCT05116462","phase":"3","status":"active"},{"id":"nct07132008","name":"Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer","nct":"NCT07132008","phase":"3","status":"planned"},{"id":"nct06437977","name":"Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)","nct":"NCT06437977","phase":"3","status":"recruiting"},{"id":"nct05429463","name":"Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE II）","nct":"NCT05429463","phase":"3","status":"recruiting"},{"id":"nct07412613","name":"Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer","nct":"NCT07412613","phase":"3","status":"recruiting"},{"id":"nct04564157","name":"New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy","nct":"NCT04564157","phase":"3","status":"active"},{"id":"nct03348904","name":"Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer","nct":"NCT03348904","phase":"3"},{"id":"nct03391869","name":"Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer","nct":"NCT03391869","phase":"3","status":"active"},{"id":"nct04335669","name":"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC","nct":"NCT04335669","phase":"3","status":"active"},{"id":"optimice-pcr","name":"OptimICE-pCR (A012103)","nct":"NCT05812807","phase":"3","status":"recruiting"},{"id":"nct05236972","name":"PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer","nct":"NCT05236972","phase":"3","status":"recruiting"},{"id":"nct07277842","name":"PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer","nct":"NCT07277842","phase":"3","status":"planned"},{"id":"nct03774732","name":"PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer","nct":"NCT03774732","phase":"3","status":"active"},{"id":"nct07486687","name":"Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy","nct":"NCT07486687","phase":"3","status":"planned"},{"id":"nct04547504","name":"PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %","nct":"NCT04547504","phase":"3","status":"active"},{"id":"nct06422143","name":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287","nct":"NCT06422143","phase":"3","status":"recruiting"},{"id":"nct06606730","name":"Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer","nct":"NCT06606730","phase":"3","status":"recruiting"},{"id":"nct06430866","name":"Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)","nct":"NCT06430866","phase":"3","status":"active"},{"id":"nct07162883","name":"Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)","nct":"NCT07162883","phase":"3","status":"planned"},{"id":"nct06467357","name":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","nct":"NCT06467357","phase":"3","status":"recruiting"},{"id":"nct07383116","name":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous No","nct":"NCT07383116","phase":"3","status":"planned"},{"id":"nct06396065","name":"Phase III Study of AK112 for NSCLC Patients","nct":"NCT06396065","phase":"3","status":"active"},{"id":"nct07829549","name":"Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Act","nct":"NCT07829549","phase":"3","status":"planned"},{"id":"nct06921785","name":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","nct":"NCT06921785","phase":"3","status":"recruiting"},{"id":"nct07170995","name":"Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Adva","nct":"NCT07170995","phase":"3","status":"recruiting"},{"id":"nct06889688","name":"Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer","nct":"NCT06889688","phase":"3","status":"recruiting"},{"id":"nct05687266","name":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","nct":"NCT05687266","phase":"3","status":"active"},{"id":"nct06357533","name":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥","nct":"NCT06357533","phase":"3","status":"recruiting"},{"id":"nct04624204","name":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-","nct":"NCT04624204","phase":"3","status":"active"},{"id":"prism-mel-301","name":"PRISM-MEL-301","nct":"NCT06112314","phase":"3","status":"recruiting"},{"id":"nct06762405","name":"PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-defi","nct":"NCT06762405","phase":"3","status":"recruiting"},{"id":"nct06109779","name":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","nct":"NCT06109779","phase":"3","status":"active"},{"id":"nct06170788","name":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P","nct":"NCT06170788","phase":"3","status":"recruiting"},{"id":"nct06393374","name":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)","nct":"NCT06393374","phase":"3","status":"recruiting"},{"id":"scarlet-s2212","name":"SCARLET (SWOG S2212)","nct":"NCT05929768","phase":"3","status":"recruiting"},{"id":"nct07431281","name":"Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2","nct":"NCT07431281","phase":"3","status":"recruiting"},{"id":"stamp-merkel","name":"STAMP (EA6174)","nct":"NCT03712605","phase":"3","status":"active"},{"id":"nct06598527","name":"Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant The","nct":"NCT06598527","phase":"3","status":"recruiting"},{"id":"nct04674683","name":"Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma","nct":"NCT04674683","phase":"3","status":"active"},{"id":"nct05215340","name":"Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionab","nct":"NCT05215340","phase":"3","status":"active"},{"id":"nct06726265","name":"Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy ","nct":"NCT06726265","phase":"3","status":"active"},{"id":"nct06584032","name":"Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer","nct":"NCT06584032","phase":"3","status":"recruiting"},{"id":"nct06585410","name":"Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma","nct":"NCT06585410","phase":"3","status":"recruiting"},{"id":"nct06890598","name":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","nct":"NCT06890598","phase":"3","status":"recruiting"},{"id":"nct04634877","name":"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)","nct":"NCT04634877","phase":"3","status":"active"},{"id":"nct05609968","name":"Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)","nct":"NCT05609968","phase":"3","status":"active"},{"id":"nct04895358","name":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","nct":"NCT04895358","phase":"3","status":"active"},{"id":"nct05239741","name":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","nct":"NCT05239741","phase":"3","status":"active"},{"id":"nct05173987","name":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)","nct":"NCT05173987","phase":"3","status":"active"},{"id":"nct03725059","name":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","nct":"NCT03725059","phase":"3","status":"active"},{"id":"nct07777822","name":"Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mu","nct":"NCT07777822","phase":"3","status":"recruiting"},{"id":"nct04380636","name":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","nct":"NCT04380636","phase":"3","status":"active"},{"id":"nct05855200","name":"Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer","nct":"NCT05855200","phase":"3","status":"recruiting"},{"id":"nct06731478","name":"Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer","nct":"NCT06731478","phase":"3","status":"recruiting"},{"id":"nct06072612","name":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","nct":"NCT06072612","phase":"3","status":"recruiting"},{"id":"nct06704620","name":"Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Can","nct":"NCT06704620","phase":"3","status":"planned"},{"id":"nct03967977","name":"Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma","nct":"NCT03967977","phase":"3","status":"active"},{"id":"nct06899126","name":"Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer","nct":"NCT06899126","phase":"3","status":"recruiting"},{"id":"nct06431633","name":"Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.","nct":"NCT06431633","phase":"3","status":"recruiting"},{"id":"nct04410445","name":"Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence","nct":"NCT04410445","phase":"3"},{"id":"nct07221734","name":"Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma","nct":"NCT07221734","phase":"3","status":"recruiting"},{"id":"nct04342910","name":"Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC","nct":"NCT04342910","phase":"3","status":"recruiting"},{"id":"nct05727904","name":"Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.","nct":"NCT05727904","phase":"3","status":"recruiting"},{"id":"swog-s1418","name":"SWOG S1418 / NRG BR006","nct":"NCT02954874","phase":"3","status":"active"},{"id":"nct07633873","name":"SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNST","nct":"NCT07633873","phase":"3","status":"planned"},{"id":"nct05549297","name":"Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)","nct":"NCT05549297","phase":"3","status":"recruiting"},{"id":"nct06908993","name":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated","nct":"NCT06908993","phase":"3","status":"recruiting"},{"id":"nct04267848","name":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Ch","nct":"NCT04267848","phase":"3","status":"recruiting"},{"id":"nct03793179","name":"Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer","nct":"NCT03793179","phase":"3","status":"active"},{"id":"nct06490536","name":"The Sagittarius Trial","nct":"NCT06490536","phase":"3","status":"recruiting"},{"id":"nct06758401","name":"This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lu","nct":"NCT06758401","phase":"3","status":"recruiting"},{"id":"nct06332274","name":"tislelizUMaB in canceR Patients With molEcuLar residuaL Disease","nct":"NCT06332274","phase":"3","status":"recruiting"},{"id":"nct04301739","name":"to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versu","nct":"NCT04301739","phase":"3","status":"planned"},{"id":"nct05468489","name":"To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC","nct":"NCT05468489","phase":"3","status":"active"},{"id":"nct06441344","name":"Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell","nct":"NCT06441344","phase":"3","status":"planned"},{"id":"tropion-breast03","name":"TROPION-Breast03","nct":"NCT05629585","phase":"3","status":"active"},{"id":"tropion-breast05","name":"TROPION-Breast05","nct":"NCT06103864","phase":"3","status":"recruiting"},{"id":"nct06264180","name":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]","nct":"NCT06264180","phase":"3","status":"recruiting"},{"id":"nct07750158","name":"Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease","nct":"NCT07750158","phase":"3","status":"recruiting"},{"id":"nct04082364","name":"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer","nct":"NCT04082364","phase":"2/3","status":"completed"},{"id":"keynote-483","name":"IND.227 / KEYNOTE-483","nct":"NCT02784171","phase":"2/3","status":"positive"},{"id":"relativity-047","name":"RELATIVITY-047","nct":"NCT03470922","phase":"2/3","status":"positive"},{"id":"orient-32","name":"ORIENT-32","nct":"NCT03794440","phase":"2/3","status":"positive"},{"id":"keynote-010","name":"KEYNOTE-010","nct":"NCT01905657","phase":"2/3","status":"positive"},{"id":"nct04547166","name":"A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Meta","nct":"NCT04547166","phase":"2/3","status":"recruiting"},{"id":"nct07318883","name":"A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab","nct":"NCT07318883","phase":"2/3","status":"planned"},{"id":"nct06335355","name":"A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients","nct":"NCT06335355","phase":"2/3","status":"planned"},{"id":"nct06361888","name":"A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer","nct":"NCT06361888","phase":"2/3","status":"recruiting"},{"id":"nct06581406","name":"A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult P","nct":"NCT06581406","phase":"2/3","status":"recruiting"},{"id":"nct06312982","name":"A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer","nct":"NCT06312982","phase":"2/3","status":"recruiting"},{"id":"nct07739186","name":"A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment f","nct":"NCT07739186","phase":"2/3","status":"planned"},{"id":"nct07554456","name":"A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)","nct":"NCT07554456","phase":"2/3","status":"recruiting"},{"id":"nct07815665","name":"A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma","nct":"NCT07815665","phase":"2/3","status":"recruiting"},{"id":"nct05980481","name":"A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer","nct":"NCT05980481","phase":"2/3","status":"active"},{"id":"nct07221149","name":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)","nct":"NCT07221149","phase":"2/3","status":"recruiting"},{"id":"nct05785767","name":"A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small","nct":"NCT05785767","phase":"2/3","status":"active"},{"id":"nct05800015","name":"A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult ","nct":"NCT05800015","phase":"2/3","status":"active"},{"id":"nct06616584","name":"Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemoth","nct":"NCT06616584","phase":"2/3","status":"recruiting"},{"id":"nct06221748","name":"DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy","nct":"NCT06221748","phase":"2/3","status":"recruiting"},{"id":"ea2197-ivonescimab","name":"EA2197 ivonescimab: ivonescimab with gemcitabine and cisplatin versus standard chemo-immunotherapy in advanced biliary tract cancer","nct":"NCT07765433","phase":"2/3","status":"planned"},{"id":"fortifi-hn01","name":"FORTIFI-HN01","nct":"NCT06788990","phase":"2/3","status":"recruiting"},{"id":"nct05987332","name":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","nct":"NCT05987332","phase":"2/3","status":"active"},{"id":"nct06493552","name":"Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors","nct":"NCT06493552","phase":"2/3","status":"recruiting"},{"id":"nct06443671","name":"Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer","nct":"NCT06443671","phase":"2/3","status":"planned"},{"id":"nct06280495","name":"Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients","nct":"NCT06280495","phase":"2/3","status":"recruiting"},{"id":"nct04613596","name":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G","nct":"NCT04613596","phase":"2/3","status":"recruiting"},{"id":"nct06947928","name":"Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Car","nct":"NCT06947928","phase":"2/3","status":"recruiting"},{"id":"nct06712316","name":"Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer","nct":"NCT06712316","phase":"2/3","status":"recruiting"},{"id":"nct05484024","name":"Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer","nct":"NCT05484024","phase":"2/3","status":"planned"},{"id":"nct07598318","name":"Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations","nct":"NCT07598318","phase":"2/3","status":"planned"},{"id":"nct04093167","name":"Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer","nct":"NCT04093167","phase":"2/3","status":"active"},{"id":"nct07662811","name":"SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer","nct":"NCT07662811","phase":"2/3","status":"planned"},{"id":"nct04929041","name":"Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Pati","nct":"NCT04929041","phase":"2/3","status":"active"},{"id":"nct05096663","name":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer","nct":"NCT05096663","phase":"2/3","status":"active"},{"id":"i-spy-2-2","name":"I-SPY 2.2","nct":"NCT01042379","phase":"platform","status":"recruiting"},{"id":"lung-map","name":"Lung-MAP (SWOG S1400 and S1900)","nct":"NCT02154490","phase":"platform","status":"completed"},{"id":"nci-match","name":"NCI-MATCH (EAY131)","nct":"NCT02465060","phase":"platform","status":"active"},{"id":"i-spy-2","name":"I-SPY 2","nct":"NCT01042379","phase":"platform","status":"active"},{"id":"alchemist","name":"ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)","nct":"NCT02194738","phase":"platform","status":"active"},{"id":"nct06099782","name":"A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol","nct":"NCT06099782","phase":"2","status":"active"},{"id":"nct04225117","name":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","nct":"NCT04225117","phase":"2","status":"active"},{"id":"nct06101134","name":"A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed","nct":"NCT06101134","phase":"2","status":"active"},{"id":"azur-1","name":"AZUR-1","nct":"NCT05723562","phase":"2","status":"positive"},{"id":"nct04895722","name":"Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) ","nct":"NCT04895722","phase":"2","status":"active"},{"id":"nct05287113","name":"Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","nct":"NCT05287113","phase":"2","status":"active"},{"id":"pod1um-201","name":"POD1UM-201 (retifanlimab in advanced Merkel cell carcinoma)","nct":"NCT03599713","phase":"2","status":"positive"},{"id":"nct04524689","name":"Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC","nct":"NCT04524689","phase":"2"},{"id":"intuitt-nf2","name":"INTUITT-NF2","nct":"NCT04374305","phase":"2","status":"recruiting"},{"id":"neopact","name":"NeoPACT","nct":"NCT03639948","phase":"2","status":"positive"},{"id":"admec-o","name":"ADMEC-O (adjuvant nivolumab in completely resected Merkel cell carcinoma)","nct":"NCT02196961","phase":"2","status":"mixed"},{"id":"c-trak-tn","name":"c-TRAK TN","nct":"NCT03145961","phase":"2","status":"completed"},{"id":"lung-map-s1800a","name":"Lung-MAP S1800A: ramucirumab plus pembrolizumab","nct":"NCT03971474","phase":"2","status":"positive"},{"id":"neoadjuvant-cemiplimab-cscc","name":"Neoadjuvant cemiplimab for resectable stage II to IV skin squamous cell carcinoma","nct":"NCT04154943","phase":"2","status":"positive"},{"id":"niche-2","name":"NICHE-2","nct":"NCT03026140","phase":"2","status":"positive"},{"id":"swog-s1801","name":"SWOG S1801","nct":"NCT03698019","phase":"2","status":"positive"},{"id":"cave","name":"CAVE mCRC","nct":"NCT04561336","phase":"2","status":"positive"},{"id":"cemiplimab-advanced-bcc","name":"Cemiplimab in basal cell carcinoma after a hedgehog inhibitor","nct":"NCT03132636","phase":"2","status":"positive"},{"id":"fmt-pd1-refractory-melanoma-pitt","name":"FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)","nct":"NCT03341143","phase":"2","status":"completed"},{"id":"dart-s1609","name":"DART (SWOG S1609): nivolumab plus ipilimumab in rare tumours","nct":"NCT02834013","phase":"2","status":"active"},{"id":"keynote-057","name":"KEYNOTE-057","nct":"NCT02625961","phase":"2","status":"positive"},{"id":"keynote-158","name":"KEYNOTE-158","nct":"NCT02628067","phase":"2","status":"active"},{"id":"keynote-629","name":"KEYNOTE-629","nct":"NCT03284424","phase":"2","status":"positive"},{"id":"tapur","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","nct":"NCT02693535","phase":"2","status":"recruiting"},{"id":"keynote-170","name":"KEYNOTE-170","nct":"NCT02576990","phase":"2","status":"positive"},{"id":"checkmate-142","name":"CheckMate 142","nct":"NCT02060188","phase":"2","status":"positive"},{"id":"checkmate-204","name":"CheckMate 204","nct":"NCT02320058","phase":"2","status":"positive"},{"id":"empower-cscc-1","name":"EMPOWER-CSCC-1","nct":"NCT02760498","phase":"2","status":"positive"},{"id":"nci9673","name":"NCI9673","nct":"NCT02314169","phase":"2","status":"mixed"},{"id":"sarc028","name":"SARC028","nct":"NCT02301039","phase":"2","status":"mixed"},{"id":"checkmate-205","name":"CheckMate 205","nct":"NCT02181738","phase":"2","status":"positive"},{"id":"keynote-017","name":"KEYNOTE-017 (Cancer Immunotherapy Trials Network 09)","nct":"NCT02267603","phase":"2","status":"positive"},{"id":"nct06856837","name":"- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorec","nct":"NCT06856837","phase":"2","status":"recruiting"},{"id":"nct06829355","name":"\"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer\"","nct":"NCT06829355","phase":"2","status":"recruiting"},{"id":"nct07779694","name":"16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer","nct":"NCT07779694","phase":"2","status":"planned"},{"id":"nct06823427","name":"9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma","nct":"NCT06823427","phase":"2","status":"recruiting"},{"id":"nct07314723","name":"9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer","nct":"NCT07314723","phase":"2","status":"recruiting"},{"id":"nct06492005","name":"A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer","nct":"NCT06492005","phase":"2","status":"recruiting"},{"id":"nct06961006","name":"A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)","nct":"NCT06961006","phase":"2","status":"recruiting"},{"id":"nct05913089","name":"A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer","nct":"NCT05913089","phase":"2","status":"recruiting"},{"id":"nct06979908","name":"A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal C","nct":"NCT06979908","phase":"2","status":"recruiting"},{"id":"nct07395063","name":"A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.","nct":"NCT07395063","phase":"2","status":"planned"},{"id":"nct05787613","name":"A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients","nct":"NCT05787613","phase":"2","status":"active"},{"id":"nct05934331","name":"A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study","nct":"NCT05934331","phase":"2","status":"recruiting"},{"id":"nct06878625","name":"A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer","nct":"NCT06878625","phase":"2","status":"recruiting"},{"id":"nct07669220","name":"A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Cours","nct":"NCT07669220","phase":"2","status":"recruiting"},{"id":"nct06936644","name":"A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation","nct":"NCT06936644","phase":"2","status":"planned"},{"id":"nct06246110","name":"A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC","nct":"NCT06246110","phase":"2","status":"active"},{"id":"nct05024097","name":"A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for","nct":"NCT05024097","phase":"2","status":"recruiting"},{"id":"nct07233850","name":"A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","nct":"NCT07233850","phase":"2","status":"planned"},{"id":"nct07052253","name":"A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.","nct":"NCT07052253","phase":"2","status":"recruiting"},{"id":"nct07331155","name":"A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]","nct":"NCT07331155","phase":"2","status":"recruiting"},{"id":"nct06218888","name":"A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Micro","nct":"NCT06218888","phase":"2","status":"planned"},{"id":"nct07253142","name":"A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer","nct":"NCT07253142","phase":"2","status":"recruiting"},{"id":"nct07390383","name":"A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]","nct":"NCT07390383","phase":"2","status":"recruiting"},{"id":"nct07058012","name":"A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal","nct":"NCT07058012","phase":"2","status":"recruiting"},{"id":"nct07604909","name":"A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy","nct":"NCT07604909","phase":"2","status":"recruiting"},{"id":"nct07669779","name":"A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer","nct":"NCT07669779","phase":"2","status":"recruiting"},{"id":"nct07743190","name":"A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) P","nct":"NCT07743190","phase":"2","status":"recruiting"},{"id":"nct07560111","name":"A Phase II Study of GC101 in NSCLC","nct":"NCT07560111","phase":"2","status":"recruiting"},{"id":"nct07506109","name":"A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colo","nct":"NCT07506109","phase":"2","status":"recruiting"},{"id":"nct07171606","name":"A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients","nct":"NCT07171606","phase":"2","status":"recruiting"},{"id":"nct05231850","name":"A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage II and Stage III Colon Cancer and dMMR/MSI.","nct":"NCT05231850","phase":"2","status":"planned"},{"id":"nct07815223","name":"A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC","nct":"NCT07815223","phase":"2","status":"recruiting"},{"id":"nct07269782","name":"A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC","nct":"NCT07269782","phase":"2","status":"recruiting"},{"id":"nct07444437","name":"A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer","nct":"NCT07444437","phase":"2","status":"recruiting"},{"id":"nct07521852","name":"A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Part","nct":"NCT07521852","phase":"2","status":"recruiting"},{"id":"nct06062420","name":"A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202","nct":"NCT06062420","phase":"2","status":"active"},{"id":"nct05565378","name":"A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer","nct":"NCT05565378","phase":"2","status":"active"},{"id":"nct07543848","name":"A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemot","nct":"NCT07543848","phase":"2","status":"planned"},{"id":"nct04501523","name":"A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC","nct":"NCT04501523","phase":"2","status":"recruiting"},{"id":"nct07054242","name":"A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Ca","nct":"NCT07054242","phase":"2","status":"planned"},{"id":"nct07101614","name":"A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy fo","nct":"NCT07101614","phase":"2","status":"planned"},{"id":"nct05329766","name":"A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies","nct":"NCT05329766","phase":"2","status":"active"},{"id":"nct05309421","name":"A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma","nct":"NCT05309421","phase":"2","status":"active"},{"id":"nct06822543","name":"A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cance","nct":"NCT06822543","phase":"2","status":"recruiting"},{"id":"nct07268677","name":"A Single-arm Clinical Study Evaluating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant Chemotherapy for Colorectal Cancer Patients With Peri","nct":"NCT07268677","phase":"2","status":"planned"},{"id":"nct07527026","name":"A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS","nct":"NCT07527026","phase":"2","status":"recruiting"},{"id":"nct06423170","name":"A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs","nct":"NCT06423170","phase":"2","status":"recruiting"},{"id":"nct06654947","name":"A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.","nct":"NCT06654947","phase":"2","status":"planned"},{"id":"nct07415031","name":"A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies","nct":"NCT07415031","phase":"2","status":"recruiting"},{"id":"nct07807163","name":"A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC","nct":"NCT07807163","phase":"2","status":"recruiting"},{"id":"nct06307431","name":"A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).","nct":"NCT06307431","phase":"2","status":"active"},{"id":"nct05859750","name":"A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer","nct":"NCT05859750","phase":"2","status":"recruiting"},{"id":"nct05382442","name":"A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer","nct":"NCT05382442","phase":"2","status":"active"},{"id":"nct07054567","name":"A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer","nct":"NCT07054567","phase":"2","status":"recruiting"},{"id":"nct06978114","name":"A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer","nct":"NCT06978114","phase":"2","status":"recruiting"},{"id":"nct06962787","name":"A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer","nct":"NCT06962787","phase":"2","status":"recruiting"},{"id":"nct07264816","name":"A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NS","nct":"NCT07264816","phase":"2","status":"recruiting"},{"id":"nct07492680","name":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)","nct":"NCT07492680","phase":"2","status":"recruiting"},{"id":"nct07227636","name":"A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy","nct":"NCT07227636","phase":"2","status":"recruiting"},{"id":"nct06843434","name":"A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma","nct":"NCT06843434","phase":"2","status":"recruiting"},{"id":"nct06465329","name":"A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Ce","nct":"NCT06465329","phase":"2","status":"active"},{"id":"nct07412262","name":"A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and Hig","nct":"NCT07412262","phase":"2","status":"recruiting"},{"id":"nct04879329","name":"A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2","nct":"NCT04879329","phase":"2","status":"recruiting"},{"id":"nct07108270","name":"A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)","nct":"NCT07108270","phase":"2","status":"recruiting"},{"id":"nct06317311","name":"A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer","nct":"NCT06317311","phase":"2","status":"active"},{"id":"nct06640049","name":"A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China","nct":"NCT06640049","phase":"2","status":"active"},{"id":"nct05217446","name":"A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic","nct":"NCT05217446","phase":"2","status":"active"},{"id":"nct06623136","name":"A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer","nct":"NCT06623136","phase":"2","status":"recruiting"},{"id":"nct06703398","name":"A Study of GC101 TIL in Advanced Melanoma","nct":"NCT06703398","phase":"2","status":"recruiting"},{"id":"nct06081920","name":"A Study of IBI363 in Subjects With Advanced Melanoma","nct":"NCT06081920","phase":"2","status":"recruiting"},{"id":"nct06281678","name":"A Study of IBI363 in Subjects with Advanced Solid Malignancies","nct":"NCT06281678","phase":"2","status":"recruiting"},{"id":"nct05805501","name":"A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cel","nct":"NCT05805501","phase":"2","status":"active"},{"id":"nct07221474","name":"A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","nct":"NCT07221474","phase":"2","status":"recruiting"},{"id":"nct07245446","name":"A Study of Ivonescimab in First-Line ES-SCLC","nct":"NCT07245446","phase":"2","status":"recruiting"},{"id":"nct07669415","name":"A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors","nct":"NCT07669415","phase":"2","status":"recruiting"},{"id":"nct06730347","name":"A Study of Lorigerlimab in Participants With Advanced Solid Tumors","nct":"NCT06730347","phase":"2","status":"recruiting"},{"id":"nct06378177","name":"A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)","nct":"NCT06378177","phase":"2","status":"active"},{"id":"nct06567782","name":"A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer","nct":"NCT06567782","phase":"2","status":"recruiting"},{"id":"nct07069712","name":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","nct":"NCT07069712","phase":"2","status":"recruiting"},{"id":"nct07098338","name":"A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)","nct":"NCT07098338","phase":"2","status":"recruiting"},{"id":"nct06041802","name":"A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)","nct":"NCT06041802","phase":"2","status":"active"},{"id":"nct06731907","name":"A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34","nct":"NCT06731907","phase":"2","status":"recruiting"},{"id":"nct04683679","name":"A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negat","nct":"NCT04683679","phase":"2","status":"recruiting"},{"id":"nct06155396","name":"A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent o","nct":"NCT06155396","phase":"2","status":"recruiting"},{"id":"nct07040644","name":"A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC","nct":"NCT07040644","phase":"2","status":"planned"},{"id":"nct05816252","name":"A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-","nct":"NCT05816252","phase":"2","status":"active"},{"id":"nct07019675","name":"A Study of SKB518 in Patients With Lung Cancer","nct":"NCT07019675","phase":"2","status":"recruiting"},{"id":"nct07622186","name":"A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)","nct":"NCT07622186","phase":"2","status":"recruiting"},{"id":"nct06971614","name":"A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC","nct":"NCT06971614","phase":"2","status":"recruiting"},{"id":"nct05635708","name":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer","nct":"NCT05635708","phase":"2","status":"active"},{"id":"nct05852691","name":"A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer","nct":"NCT05852691","phase":"2","status":"active"},{"id":"nct03505320","name":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","nct":"NCT03505320","phase":"2","status":"active"},{"id":"nct06944106","name":"A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer","nct":"NCT06944106","phase":"2","status":"recruiting"},{"id":"nct07005336","name":"A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untr","nct":"NCT07005336","phase":"2","status":"active"},{"id":"nct07554521","name":"A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States","nct":"NCT07554521","phase":"2","status":"recruiting"},{"id":"nct05318573","name":"A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer","nct":"NCT05318573","phase":"2","status":"active"},{"id":"nct06797297","name":"A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastat","nct":"NCT06797297","phase":"2","status":"recruiting"},{"id":"nct07811193","name":"A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum","nct":"NCT07811193","phase":"2","status":"recruiting"},{"id":"nct06948448","name":"A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard ","nct":"NCT06948448","phase":"2","status":"recruiting"},{"id":"nct06946797","name":"A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Pre","nct":"NCT06946797","phase":"2","status":"active"},{"id":"nct06349980","name":"A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.","nct":"NCT06349980","phase":"2","status":"recruiting"},{"id":"nct05954429","name":"A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-cente","nct":"NCT05954429","phase":"2","status":"recruiting"},{"id":"nct07475806","name":"A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder","nct":"NCT07475806","phase":"2","status":"recruiting"},{"id":"nct06256328","name":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","nct":"NCT06256328","phase":"2","status":"active"},{"id":"nct06008093","name":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS","nct":"NCT06008093","phase":"2","status":"active"},{"id":"nct06769698","name":"A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous ","nct":"NCT06769698","phase":"2","status":"recruiting"},{"id":"nct06632405","name":"A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC","nct":"NCT06632405","phase":"2","status":"planned"},{"id":"nct06679985","name":"A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepat","nct":"NCT06679985","phase":"2","status":"active"},{"id":"nct05557591","name":"A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small ","nct":"NCT05557591","phase":"2","status":"active"},{"id":"nct06190951","name":"A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma","nct":"NCT06190951","phase":"2","status":"active"},{"id":"nct06161441","name":"A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemoth","nct":"NCT06161441","phase":"2","status":"active"},{"id":"nct07746388","name":"Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial","nct":"NCT07746388","phase":"2","status":"planned"},{"id":"nct05825443","name":"Adjuvant Chemotherapy Combined With Camrelizumab for IIA -IIIA NSCLC Patients","nct":"NCT05825443","phase":"2","status":"recruiting"},{"id":"nct04317534","name":"Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm","nct":"NCT04317534","phase":"2","status":"recruiting"},{"id":"nct05601752","name":"ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)","nct":"NCT05601752","phase":"2","status":"active"},{"id":"nct06638931","name":"Agnostic Therapy in Rare Solid Tumors","nct":"NCT06638931","phase":"2","status":"recruiting"},{"id":"nct05932212","name":"AK104 for Recurrent or Metastatic Vulvar Cancer","nct":"NCT05932212","phase":"2","status":"recruiting"},{"id":"nct07544784","name":"AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)","nct":"NCT07544784","phase":"2","status":"recruiting"},{"id":"nct07767994","name":"AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer","nct":"NCT07767994","phase":"2","status":"planned"},{"id":"nct07158840","name":"AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor","nct":"NCT07158840","phase":"2","status":"planned"},{"id":"nct05247684","name":"AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC","nct":"NCT05247684","phase":"2","status":"active"},{"id":"nct07021950","name":"AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer","nct":"NCT07021950","phase":"2","status":"planned"},{"id":"nct06636981","name":"All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi","nct":"NCT06636981","phase":"2","status":"recruiting"},{"id":"nct04443543","name":"An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer","nct":"NCT04443543","phase":"2","status":"planned"},{"id":"nct03897881","name":"An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYN","nct":"NCT03897881","phase":"2","status":"active"},{"id":"nct06560112","name":"An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer","nct":"NCT06560112","phase":"2","status":"recruiting"},{"id":"nct07398326","name":"Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer","nct":"NCT07398326","phase":"2","status":"recruiting"},{"id":"nct07635290","name":"Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer","nct":"NCT07635290","phase":"2","status":"active"},{"id":"nct05841472","name":"Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metas","nct":"NCT05841472","phase":"2","status":"recruiting"},{"id":"nct07015853","name":"ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation","nct":"NCT07015853","phase":"2","status":"planned"},{"id":"nct07550088","name":"BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases","nct":"NCT07550088","phase":"2","status":"recruiting"},{"id":"nct07486817","name":"Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab","nct":"NCT07486817","phase":"2","status":"recruiting"},{"id":"nct07649980","name":"Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II","nct":"NCT07649980","phase":"2","status":"planned"},{"id":"nct07722754","name":"Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial","nct":"NCT07722754","phase":"2","status":"recruiting"},{"id":"nct07610525","name":"Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial","nct":"NCT07610525","phase":"2","status":"planned"},{"id":"nct07226856","name":"BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma","nct":"NCT07226856","phase":"2","status":"recruiting"},{"id":"nct07645118","name":"Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer","nct":"NCT07645118","phase":"2","status":"planned"},{"id":"nct04933903","name":"BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab","nct":"NCT04933903","phase":"2","status":"recruiting"},{"id":"nct06367088","name":"Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer","nct":"NCT06367088","phase":"2","status":"recruiting"},{"id":"nct06168786","name":"Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC","nct":"NCT06168786","phase":"2","status":"recruiting"},{"id":"nct06438822","name":"Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma","nct":"NCT06438822","phase":"2","status":"recruiting"},{"id":"nct06532617","name":"Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer","nct":"NCT06532617","phase":"2","status":"recruiting"},{"id":"nct06901622","name":"Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma","nct":"NCT06901622","phase":"2","status":"recruiting"},{"id":"nct07107217","name":"Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer","nct":"NCT07107217","phase":"2","status":"planned"},{"id":"nct05451290","name":"Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer","nct":"NCT05451290","phase":"2","status":"active"},{"id":"nct05973864","name":"Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery","nct":"NCT05973864","phase":"2","status":"recruiting"},{"id":"nct07281768","name":"Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer","nct":"NCT07281768","phase":"2","status":"recruiting"},{"id":"nct06881537","name":"CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer","nct":"NCT06881537","phase":"2","status":"recruiting"},{"id":"cemiplimab-nut","name":"Cemiplimab in metastatic or unresectable NUT carcinoma (Northwestern pilot)","nct":"NCT07050186","phase":"2","status":"recruiting"},{"id":"nct07224022","name":"Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer","nct":"NCT07224022","phase":"2","status":"planned"},{"id":"nct06205836","name":"Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer","nct":"NCT06205836","phase":"2","status":"recruiting"},{"id":"nct06547203","name":"Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study","nct":"NCT06547203","phase":"2","status":"recruiting"},{"id":"nct06652412","name":"CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC","nct":"NCT06652412","phase":"2","status":"planned"},{"id":"nct06699836","name":"CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen","nct":"NCT06699836","phase":"2","status":"active"},{"id":"nct04969887","name":"Combination Immunotherapy in Rare Cancers Under InvesTigation","nct":"NCT04969887","phase":"2","status":"active"},{"id":"nct05757336","name":"Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer","nct":"NCT05757336","phase":"2","status":"recruiting"},{"id":"nct03259867","name":"Combination of TATE and PD-1 Inhibitor in Liver Cancer","nct":"NCT03259867","phase":"2","status":"recruiting"},{"id":"nct05609578","name":"Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation","nct":"NCT05609578","phase":"2","status":"active"},{"id":"nct06686030","name":"Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer","nct":"NCT06686030","phase":"2","status":"recruiting"},{"id":"nct05909423","name":"Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer","nct":"NCT05909423","phase":"2","status":"planned"},{"id":"nct06265285","name":"Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW)","nct":"NCT06265285","phase":"2","status":"recruiting"},{"id":"nct06502080","name":"Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)","nct":"NCT06502080","phase":"2","status":"planned"},{"id":"nct05057052","name":"Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis","nct":"NCT05057052","phase":"2","status":"recruiting"},{"id":"nct06951646","name":"ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)","nct":"NCT06951646","phase":"2","status":"recruiting"},{"id":"nct05257590","name":"CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma","nct":"NCT05257590","phase":"2","status":"recruiting"},{"id":"nct06698757","name":"Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer","nct":"NCT06698757","phase":"2","status":"recruiting"},{"id":"nct07159217","name":"Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer","nct":"NCT07159217","phase":"2","status":"planned"},{"id":"nct05724563","name":"Domvanalimab and Zimberelimab in Advanced Liver Cancers","nct":"NCT05724563","phase":"2","status":"active"},{"id":"nct06333314","name":"Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI","nct":"NCT06333314","phase":"2","status":"recruiting"},{"id":"nct06757244","name":"DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer","nct":"NCT06757244","phase":"2","status":"recruiting"},{"id":"nct04920617","name":"DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymp","nct":"NCT04920617","phase":"2","status":"recruiting"},{"id":"nct06178159","name":"DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer","nct":"NCT06178159","phase":"2","status":"recruiting"},{"id":"nct06463665","name":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL ","nct":"NCT06463665","phase":"2","status":"recruiting"},{"id":"nct06176885","name":"Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite","nct":"NCT06176885","phase":"2","status":"recruiting"},{"id":"nct06028633","name":"Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients","nct":"NCT06028633","phase":"2","status":"planned"},{"id":"nct07638501","name":"Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer","nct":"NCT07638501","phase":"2","status":"planned"},{"id":"nct06642545","name":"Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer","nct":"NCT06642545","phase":"2","status":"recruiting"},{"id":"nct03485209","name":"Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors","nct":"NCT03485209","phase":"2","status":"active"},{"id":"eortc-1607-pembro-cisgem","name":"EORTC 1607: pembrolizumab with cisplatin and gemcitabine in biliary tract cancer","nct":"NCT03260712","phase":"2","status":"completed"},{"id":"nct04675333","name":"Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)","nct":"NCT04675333","phase":"2","status":"active"},{"id":"nct04675294","name":"Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)","nct":"NCT04675294","phase":"2","status":"active"},{"id":"nct07007767","name":"Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）","nct":"NCT07007767","phase":"2","status":"planned"},{"id":"nct07105852","name":"Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma","nct":"NCT07105852","phase":"2","status":"recruiting"},{"id":"nct07378306","name":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","nct":"NCT07378306","phase":"2","status":"recruiting"},{"id":"nct06780787","name":"FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery","nct":"NCT06780787","phase":"2","status":"recruiting"},{"id":"nct06484153","name":"Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma","nct":"NCT06484153","phase":"2","status":"recruiting"},{"id":"nct06423937","name":"Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer","nct":"NCT06423937","phase":"2","status":"planned"},{"id":"nct05749588","name":"FUSCC Refractory TNBC Platform Study (FUTURE2.0)","nct":"NCT05749588","phase":"2","status":"recruiting"},{"id":"nct06722183","name":"Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities","nct":"NCT06722183","phase":"2","status":"recruiting"},{"id":"nct06963060","name":"Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)","nct":"NCT06963060","phase":"2","status":"recruiting"},{"id":"nct07433673","name":"Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)","nct":"NCT07433673","phase":"2","status":"recruiting"},{"id":"nct07432295","name":"Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)","nct":"NCT07432295","phase":"2","status":"recruiting"},{"id":"nct06198907","name":"Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)","nct":"NCT06198907","phase":"2","status":"planned"},{"id":"nct06709885","name":"HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer","nct":"NCT06709885","phase":"2","status":"recruiting"},{"id":"nct06492759","name":"High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer","nct":"NCT06492759","phase":"2","status":"recruiting"},{"id":"nct06849492","name":"HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer","nct":"NCT06849492","phase":"2","status":"planned"},{"id":"nct06435260","name":"Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer","nct":"NCT06435260","phase":"2","status":"recruiting"},{"id":"nct07402070","name":"IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer","nct":"NCT07402070","phase":"2","status":"planned"},{"id":"nct07122687","name":"IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small","nct":"NCT07122687","phase":"2","status":"recruiting"},{"id":"nct07452224","name":"ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer","nct":"NCT07452224","phase":"2","status":"recruiting"},{"id":"nct06107374","name":"Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG","nct":"NCT06107374","phase":"2","status":"recruiting"},{"id":"nct04159818","name":"Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients","nct":"NCT04159818","phase":"2","status":"recruiting"},{"id":"nct07140679","name":"Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer","nct":"NCT07140679","phase":"2","status":"recruiting"},{"id":"nct05732389","name":"Immunotherapy in Patients With Early dMMR Rectal Cancer","nct":"NCT05732389","phase":"2","status":"recruiting"},{"id":"nct01174121","name":"Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer","nct":"NCT01174121","phase":"2","status":"recruiting"},{"id":"impact-bcc","name":"IMPACT (cemiplimab in advanced basal cell carcinoma)","nct":"ISRCTN10511385","phase":"2","status":"active"},{"id":"nct06898970","name":"Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma","nct":"NCT06898970","phase":"2","status":"recruiting"},{"id":"nct06787612","name":"Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer","nct":"NCT06787612","phase":"2","status":"recruiting"},{"id":"nct06634875","name":"Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)","nct":"NCT06634875","phase":"2","status":"recruiting"},{"id":"nct07405190","name":"Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC","nct":"NCT07405190","phase":"2","status":"recruiting"},{"id":"nct06993025","name":"Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies","nct":"NCT06993025","phase":"2","status":"planned"},{"id":"nct06848842","name":"Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases","nct":"NCT06848842","phase":"2","status":"recruiting"},{"id":"nct06991491","name":"Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)","nct":"NCT06991491","phase":"2","status":"planned"},{"id":"nct06491472","name":"Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer","nct":"NCT06491472","phase":"2","status":"recruiting"},{"id":"nct06731153","name":"JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC","nct":"NCT06731153","phase":"2","status":"planned"},{"id":"nct07481058","name":"KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer","nct":"NCT07481058","phase":"2","status":"recruiting"},{"id":"nct07252739","name":"KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)","nct":"NCT07252739","phase":"2","status":"recruiting"},{"id":"nct07620548","name":"Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas","nct":"NCT07620548","phase":"2","status":"planned"},{"id":"nct06789848","name":"Ligufalimab and Cadonilimab in Advanced Liver Cancers","nct":"NCT06789848","phase":"2","status":"recruiting"},{"id":"nct07797816","name":"Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer","nct":"NCT07797816","phase":"2","status":"recruiting"},{"id":"nct06387628","name":"LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer","nct":"NCT06387628","phase":"2","status":"recruiting"},{"id":"nct07150949","name":"Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC","nct":"NCT07150949","phase":"2","status":"recruiting"},{"id":"nct07576725","name":"Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial","nct":"NCT07576725","phase":"2","status":"planned"},{"id":"nct07448142","name":"Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer","nct":"NCT07448142","phase":"2","status":"recruiting"},{"id":"nct05360277","name":"Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer","nct":"NCT05360277","phase":"2","status":"recruiting"},{"id":"nct06759090","name":"Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer","nct":"NCT06759090","phase":"2","status":"planned"},{"id":"nct05462236","name":"MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer","nct":"NCT05462236","phase":"2","status":"recruiting"},{"id":"nct05462496","name":"Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer","nct":"NCT05462496","phase":"2","status":"recruiting"},{"id":"nct06840665","name":"MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer","nct":"NCT06840665","phase":"2","status":"recruiting"},{"id":"nct06405490","name":"NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC","nct":"NCT06405490","phase":"2","status":"recruiting"},{"id":"nct06941857","name":"NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer","nct":"NCT06941857","phase":"2","status":"recruiting"},{"id":"nct04109755","name":"Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer","nct":"NCT04109755","phase":"2","status":"recruiting"},{"id":"nct06846268","name":"Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer","nct":"NCT06846268","phase":"2","status":"recruiting"},{"id":"nct07743632","name":"Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC","nct":"NCT07743632","phase":"2","status":"planned"},{"id":"nct07595874","name":"Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3","nct":"NCT07595874","phase":"2","status":"recruiting"},{"id":"nct06790212","name":"Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer","nct":"NCT06790212","phase":"2","status":"planned"},{"id":"nct03916627","name":"Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients","nct":"NCT03916627","phase":"2","status":"active"},{"id":"nct06449313","name":"Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features","nct":"NCT06449313","phase":"2","status":"recruiting"},{"id":"nct05479240","name":"Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer","nct":"NCT05479240","phase":"2","status":"planned"},{"id":"nct05450029","name":"Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer","nct":"NCT05450029","phase":"2","status":"recruiting"},{"id":"nct07351487","name":"Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)","nct":"NCT07351487","phase":"2","status":"recruiting"},{"id":"nct06682195","name":"Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)","nct":"NCT06682195","phase":"2","status":"recruiting"},{"id":"nct06368141","name":"Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer","nct":"NCT06368141","phase":"2","status":"recruiting"},{"id":"nct07016399","name":"Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC","nct":"NCT07016399","phase":"2","status":"recruiting"},{"id":"nct05132504","name":"Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer","nct":"NCT05132504","phase":"2","status":"recruiting"},{"id":"nct07403877","name":"Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer","nct":"NCT07403877","phase":"2","status":"planned"},{"id":"nct06353997","name":"Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients","nct":"NCT06353997","phase":"2","status":"recruiting"},{"id":"nct07381400","name":"Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)","nct":"NCT07381400","phase":"2","status":"planned"},{"id":"nct07527520","name":"Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prosp","nct":"NCT07527520","phase":"2","status":"planned"},{"id":"nct07808151","name":"Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer","nct":"NCT07808151","phase":"2","status":"planned"},{"id":"nct06407310","name":"Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer","nct":"NCT06407310","phase":"2","status":"planned"},{"id":"nct07283692","name":"Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)","nct":"NCT07283692","phase":"2","status":"recruiting"},{"id":"nct06718543","name":"Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer","nct":"NCT06718543","phase":"2","status":"recruiting"},{"id":"nct06227117","name":"Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer","nct":"NCT06227117","phase":"2","status":"recruiting"},{"id":"nct07394387","name":"Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.","nct":"NCT07394387","phase":"2","status":"recruiting"},{"id":"nct07134101","name":"Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)","nct":"NCT07134101","phase":"2","status":"planned"},{"id":"nct06977542","name":"Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer","nct":"NCT06977542","phase":"2","status":"planned"},{"id":"nct06903273","name":"Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma","nct":"NCT06903273","phase":"2","status":"planned"},{"id":"nct07457359","name":"Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer","nct":"NCT07457359","phase":"2","status":"recruiting"},{"id":"nct03926338","name":"Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer","nct":"NCT03926338","phase":"2","status":"recruiting"},{"id":"nct07188246","name":"Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer","nct":"NCT07188246","phase":"2","status":"recruiting"},{"id":"nct05562297","name":"Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer","nct":"NCT05562297","phase":"2","status":"planned"},{"id":"nct04912765","name":"Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC","nct":"NCT04912765","phase":"2","status":"recruiting"},{"id":"nct06845319","name":"NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients","nct":"NCT06845319","phase":"2","status":"recruiting"},{"id":"nct07677579","name":"NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer","nct":"NCT07677579","phase":"2","status":"planned"},{"id":"nct05310643","name":"Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC","nct":"NCT05310643","phase":"2","status":"recruiting"},{"id":"nct06204094","name":"Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer","nct":"NCT06204094","phase":"2","status":"recruiting"},{"id":"nct05702229","name":"Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","nct":"NCT05702229","phase":"2","status":"recruiting"},{"id":"nct05485766","name":"Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer","nct":"NCT05485766","phase":"2","status":"recruiting"},{"id":"nct04901741","name":"Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer","nct":"NCT04901741","phase":"2","status":"planned"},{"id":"nct05446298","name":"ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer","nct":"NCT05446298","phase":"2","status":"active"},{"id":"nct06919848","name":"Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)","nct":"NCT06919848","phase":"2","status":"planned"},{"id":"nct06196671","name":"Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer","nct":"NCT06196671","phase":"2","status":"planned"},{"id":"nct06318897","name":"Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T","nct":"NCT06318897","phase":"2","status":"recruiting"},{"id":"nct07040098","name":"Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer","nct":"NCT07040098","phase":"2","status":"recruiting"},{"id":"nct06558214","name":"OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial","nct":"NCT06558214","phase":"2","status":"recruiting"},{"id":"nct07001618","name":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiot","nct":"NCT07001618","phase":"2","status":"recruiting"},{"id":"nct06390982","name":"Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study","nct":"NCT06390982","phase":"2","status":"planned"},{"id":"nct07819591","name":"Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC","nct":"NCT07819591","phase":"2","status":"planned"},{"id":"nct03899155","name":"Pan Tumor Rollover Study","nct":"NCT03899155","phase":"2","status":"recruiting"},{"id":"nct07223424","name":"Patient Preference for Subcutaneous vs. Intravenous Immune Therapy","nct":"NCT07223424","phase":"2","status":"recruiting"},{"id":"nct06788912","name":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","nct":"NCT06788912","phase":"2","status":"recruiting"},{"id":"nct06976944","name":"Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer","nct":"NCT06976944","phase":"2","status":"recruiting"},{"id":"nct04153734","name":"Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC","nct":"NCT04153734","phase":"2","status":"planned"},{"id":"nct05623319","name":"Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)","nct":"NCT05623319","phase":"2","status":"recruiting"},{"id":"nct05903833","name":"Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surge","nct":"NCT05903833","phase":"2","status":"recruiting"},{"id":"nct04976634","name":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","nct":"NCT04976634","phase":"2","status":"active"},{"id":"nct05093231","name":"Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer","nct":"NCT05093231","phase":"2","status":"recruiting"},{"id":"nct06230471","name":"Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer","nct":"NCT06230471","phase":"2","status":"recruiting"},{"id":"nct04846634","name":"Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (A","nct":"NCT04846634","phase":"2","status":"planned"},{"id":"nct07450183","name":"Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1","nct":"NCT07450183","phase":"2","status":"planned"},{"id":"nct06155383","name":"Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.","nct":"NCT06155383","phase":"2","status":"recruiting"},{"id":"nct06001658","name":"Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers","nct":"NCT06001658","phase":"2","status":"recruiting"},{"id":"nct06841159","name":"Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Can","nct":"NCT06841159","phase":"2","status":"recruiting"},{"id":"nct06245889","name":"PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC","nct":"NCT06245889","phase":"2","status":"recruiting"},{"id":"nct05945823","name":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","nct":"NCT05945823","phase":"2","status":"active"},{"id":"nct04291105","name":"Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients","nct":"NCT04291105","phase":"2","status":"active"},{"id":"nct05864534","name":"Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma","nct":"NCT05864534","phase":"2","status":"recruiting"},{"id":"nct06852287","name":"Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","nct":"NCT06852287","phase":"2","status":"recruiting"},{"id":"nct06708858","name":"Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer","nct":"NCT06708858","phase":"2","status":"recruiting"},{"id":"nct05239650","name":"Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC","nct":"NCT05239650","phase":"2","status":"planned"},{"id":"nct07003022","name":"Phase II Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC","nct":"NCT07003022","phase":"2","status":"recruiting"},{"id":"nct06959550","name":"Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer","nct":"NCT06959550","phase":"2","status":"recruiting"},{"id":"nct07487519","name":"Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Br","nct":"NCT07487519","phase":"2","status":"planned"},{"id":"nct06830239","name":"Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer","nct":"NCT06830239","phase":"2","status":"recruiting"},{"id":"nct06521866","name":"Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer","nct":"NCT06521866","phase":"2","status":"recruiting"},{"id":"nct07234877","name":"Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets","nct":"NCT07234877","phase":"2","status":"planned"},{"id":"nct07017673","name":"Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer","nct":"NCT07017673","phase":"2","status":"recruiting"},{"id":"nct06121505","name":"Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer","nct":"NCT06121505","phase":"2","status":"recruiting"},{"id":"nct06300463","name":"Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases","nct":"NCT06300463","phase":"2","status":"recruiting"},{"id":"nct05845450","name":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","nct":"NCT05845450","phase":"2","status":"recruiting"},{"id":"nct06623656","name":"Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC","nct":"NCT06623656","phase":"2","status":"recruiting"},{"id":"nct06157151","name":"PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer","nct":"NCT06157151","phase":"2","status":"recruiting"},{"id":"nct05741164","name":"Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer","nct":"NCT05741164","phase":"2","status":"recruiting"},{"id":"nct07103447","name":"Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC","nct":"NCT07103447","phase":"2","status":"planned"},{"id":"nct06745882","name":"Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC","nct":"NCT06745882","phase":"2","status":"recruiting"},{"id":"nct07586124","name":"Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma","nct":"NCT07586124","phase":"2","status":"recruiting"},{"id":"nct06770270","name":"Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)","nct":"NCT06770270","phase":"2","status":"recruiting"},{"id":"nct06788171","name":"PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM","nct":"NCT06788171","phase":"2","status":"planned"},{"id":"nct03228667","name":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","nct":"NCT03228667","phase":"2","status":"active"},{"id":"nct07774754","name":"Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical Trial","nct":"NCT07774754","phase":"2","status":"planned"},{"id":"nct06573398","name":"Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC","nct":"NCT06573398","phase":"2","status":"planned"},{"id":"nct07735624","name":"RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer","nct":"NCT07735624","phase":"2","status":"recruiting"},{"id":"nct07071961","name":"Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Di","nct":"NCT07071961","phase":"2","status":"recruiting"},{"id":"nct05963490","name":"Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","nct":"NCT05963490","phase":"2","status":"recruiting"},{"id":"nct05491226","name":"Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation","nct":"NCT05491226","phase":"2","status":"recruiting"},{"id":"nct07244874","name":"Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC","nct":"NCT07244874","phase":"2","status":"planned"},{"id":"nct04468061","name":"Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC","nct":"NCT04468061","phase":"2","status":"recruiting"},{"id":"nct04230109","name":"Sacituzumab Govitecan In TNBC","nct":"NCT04230109","phase":"2","status":"recruiting"},{"id":"nct06685276","name":"Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer","nct":"NCT06685276","phase":"2","status":"recruiting"},{"id":"nct07745790","name":"Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer","nct":"NCT07745790","phase":"2","status":"planned"},{"id":"nct03407144","name":"Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)","nct":"NCT03407144","phase":"2","status":"active"},{"id":"nct05117242","name":"Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer","nct":"NCT05117242","phase":"2","status":"withdrawn"},{"id":"nct06245356","name":"Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer","nct":"NCT06245356","phase":"2","status":"recruiting"},{"id":"nct06009029","name":"SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)","nct":"NCT06009029","phase":"2","status":"planned"},{"id":"nct07683221","name":"SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer","nct":"NCT07683221","phase":"2","status":"planned"},{"id":"nct07535632","name":"SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer","nct":"NCT07535632","phase":"2","status":"planned"},{"id":"nct06401005","name":"SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)","nct":"NCT06401005","phase":"2","status":"recruiting"},{"id":"nct07162714","name":"SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer","nct":"NCT07162714","phase":"2","status":"recruiting"},{"id":"nct05576480","name":"SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer","nct":"NCT05576480","phase":"2","status":"recruiting"},{"id":"nct06850103","name":"SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases","nct":"NCT06850103","phase":"2","status":"recruiting"},{"id":"nct06166589","name":"Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer","nct":"NCT06166589","phase":"2","status":"planned"},{"id":"nct05731726","name":"Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer","nct":"NCT05731726","phase":"2","status":"recruiting"},{"id":"nct07819604","name":"Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer","nct":"NCT07819604","phase":"2","status":"planned"},{"id":"sevilla","name":"SEVILLA","nct":"NCT06529718","phase":"2","status":"recruiting"},{"id":"nct06872606","name":"Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for","nct":"NCT06872606","phase":"2","status":"planned"},{"id":"nct06802666","name":"Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer","nct":"NCT06802666","phase":"2","status":"recruiting"},{"id":"nct07594925","name":"Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomiz","nct":"NCT07594925","phase":"2","status":"recruiting"},{"id":"nct06542588","name":"Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC","nct":"NCT06542588","phase":"2","status":"recruiting"},{"id":"nct07521605","name":"Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer","nct":"NCT07521605","phase":"2","status":"planned"},{"id":"nct07469306","name":"Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer","nct":"NCT07469306","phase":"2","status":"planned"},{"id":"nct05239546","name":"Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers","nct":"NCT05239546","phase":"2","status":"recruiting"},{"id":"nct07654530","name":"Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.","nct":"NCT07654530","phase":"2","status":"active"},{"id":"nct07656766","name":"Sintilimab Plus Gossypol Acetate in Advanced Colorectal Cancer","nct":"NCT07656766","phase":"2","status":"planned"},{"id":"nct07831993","name":"Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer","nct":"NCT07831993","phase":"2","status":"recruiting"},{"id":"nct05642780","name":"SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors","nct":"NCT05642780","phase":"2","status":"active"},{"id":"nct07700667","name":"SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma","nct":"NCT07700667","phase":"2","status":"recruiting"},{"id":"nct07022002","name":"SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors","nct":"NCT07022002","phase":"2","status":"recruiting"},{"id":"nct07646626","name":"SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors","nct":"NCT07646626","phase":"2","status":"recruiting"},{"id":"nct06525428","name":"Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","nct":"NCT06525428","phase":"2","status":"recruiting"},{"id":"nct06225596","name":"Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)","nct":"NCT06225596","phase":"2","status":"active"},{"id":"nct04050436","name":"Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer","nct":"NCT04050436","phase":"2","status":"active"},{"id":"nct04736173","name":"Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer","nct":"NCT04736173","phase":"2","status":"active"},{"id":"nct03836352","name":"Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recur","nct":"NCT03836352","phase":"2","status":"active"},{"id":"nct06202313","name":"Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer","nct":"NCT06202313","phase":"2","status":"planned"},{"id":"nct05447702","name":"Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)","nct":"NCT05447702","phase":"2","status":"recruiting"},{"id":"nct05489211","name":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","nct":"NCT05489211","phase":"2","status":"recruiting"},{"id":"nct07527858","name":"Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer","nct":"NCT07527858","phase":"2","status":"recruiting"},{"id":"nct06048133","name":"Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)","nct":"NCT06048133","phase":"2","status":"active"},{"id":"nct05775159","name":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer","nct":"NCT05775159","phase":"2","status":"active"},{"id":"nct06727565","name":"Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Subst","nct":"NCT06727565","phase":"2","status":"active"},{"id":"nct05633667","name":"Study of Novel Treatment Combinations in Patients With Lung Cancer","nct":"NCT05633667","phase":"2","status":"active"},{"id":"nct06797635","name":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","nct":"NCT06797635","phase":"2","status":"recruiting"},{"id":"nct03767348","name":"Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)","nct":"NCT03767348","phase":"2","status":"active"},{"id":"nct05186974","name":"Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)","nct":"NCT05186974","phase":"2","status":"active"},{"id":"nct03547973","name":"Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","nct":"NCT03547973","phase":"2","status":"active"},{"id":"nct06284590","name":"Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients","nct":"NCT06284590","phase":"2","status":"recruiting"},{"id":"nct03865082","name":"Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)","nct":"NCT03865082","phase":"2","status":"active"},{"id":"nct06558227","name":"Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma","nct":"NCT06558227","phase":"2","status":"recruiting"},{"id":"nct07104604","name":"Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally","nct":"NCT07104604","phase":"2","status":"recruiting"},{"id":"nct05725200","name":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","nct":"NCT05725200","phase":"2","status":"recruiting"},{"id":"nct05676931","name":"Study With Various Immunotherapy Treatments in Participants With Lung Cancer","nct":"NCT05676931","phase":"2","status":"active"},{"id":"nct05988372","name":"Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)","nct":"NCT05988372","phase":"2","status":"planned"},{"id":"nct06531291","name":"Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation","nct":"NCT06531291","phase":"2","status":"planned"},{"id":"nct07469956","name":"Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer","nct":"NCT07469956","phase":"2","status":"planned"},{"id":"nct05570825","name":"SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer","nct":"NCT05570825","phase":"2","status":"recruiting"},{"id":"nct07786428","name":"Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC","nct":"NCT07786428","phase":"2","status":"planned"},{"id":"nct04701476","name":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","nct":"NCT04701476","phase":"2","status":"recruiting"},{"id":"nct07583511","name":"Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study","nct":"NCT07583511","phase":"2","status":"recruiting"},{"id":"nct07359456","name":"Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases","nct":"NCT07359456","phase":"2","status":"planned"},{"id":"nct07551596","name":"Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial","nct":"NCT07551596","phase":"2","status":"recruiting"},{"id":"nct06254521","name":"The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer","nct":"NCT06254521","phase":"2","status":"recruiting"},{"id":"nct07565285","name":"The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma","nct":"NCT07565285","phase":"2","status":"recruiting"},{"id":"nct07514533","name":"The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma","nct":"NCT07514533","phase":"2","status":"planned"},{"id":"nct06843551","name":"The Miami \"EMPIRE\" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation","nct":"NCT06843551","phase":"2","status":"recruiting"},{"id":"nct06735131","name":"The Optimal Radioimmunotherapy Combinations for Advanced TNBC","nct":"NCT06735131","phase":"2","status":"recruiting"},{"id":"nct05208944","name":"THIO Sequenced With Cemiplimab in Advanced NSCLC","nct":"NCT05208944","phase":"2","status":"active"},{"id":"nct06865339","name":"Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer","nct":"NCT06865339","phase":"2","status":"recruiting"},{"id":"nct03736889","name":"Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors","nct":"NCT03736889","phase":"2","status":"recruiting"},{"id":"nct05841134","name":"Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer","nct":"NCT05841134","phase":"2","status":"planned"},{"id":"nct06538896","name":"Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Mu","nct":"NCT06538896","phase":"2","status":"recruiting"},{"id":"nct06529523","name":"Tislelizumab in People With Colorectal Cancer","nct":"NCT06529523","phase":"2","status":"recruiting"},{"id":"nct06389006","name":"To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer","nct":"NCT06389006","phase":"2","status":"recruiting"},{"id":"nct07468630","name":"Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma","nct":"NCT07468630","phase":"2","status":"recruiting"},{"id":"nct07256964","name":"Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer","nct":"NCT07256964","phase":"2","status":"planned"},{"id":"nct06717464","name":"Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer","nct":"NCT06717464","phase":"2","status":"active"},{"id":"nct06903858","name":"Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer","nct":"NCT06903858","phase":"2","status":"recruiting"},{"id":"nct07819578","name":"Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC","nct":"NCT07819578","phase":"2","status":"planned"},{"id":"nct06940388","name":"Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.","nct":"NCT06940388","phase":"2","status":"recruiting"},{"id":"nct06951399","name":"Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer","nct":"NCT06951399","phase":"2","status":"planned"},{"id":"trap-btc","name":"TRAP-BTC","nct":"NCT06178445","phase":"2","status":"active"},{"id":"nct07506057","name":"Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy","nct":"NCT07506057","phase":"2","status":"recruiting"},{"id":"nct06304545","name":"Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab","nct":"NCT06304545","phase":"2","status":"planned"},{"id":"nct04875585","name":"Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC","nct":"NCT04875585","phase":"2","status":"recruiting"},{"id":"nct06371807","name":"Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab","nct":"NCT06371807","phase":"2","status":"planned"},{"id":"nct07246863","name":"Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC","nct":"NCT07246863","phase":"2","status":"recruiting"},{"id":"nct07098988","name":"Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC","nct":"NCT07098988","phase":"2","status":"recruiting"},{"id":"nct04966663","name":"Using ctDNA to Determine Therapies for Lung Cancer","nct":"NCT04966663","phase":"2","status":"recruiting"},{"id":"nct07765836","name":"Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC","nct":"NCT07765836","phase":"2","status":"planned"},{"id":"nct07219459","name":"Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)","nct":"NCT07219459","phase":"2","status":"recruiting"},{"id":"nct05771181","name":"Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients","nct":"NCT05771181","phase":"2","status":"recruiting"},{"id":"nct06523049","name":"Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy","nct":"NCT06523049","phase":"2","status":"planned"},{"id":"nct07381777","name":"XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC)","nct":"NCT07381777","phase":"2","status":"planned"},{"id":"nct05609370","name":"A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus ","nct":"NCT05609370","phase":"1/2","status":"active"},{"id":"cemiplimab-kidney-transplant-cscc","name":"Cemiplimab for kidney transplant recipients with advanced skin squamous cell carcinoma","nct":"NCT04339062","phase":"1/2","status":"positive"},{"id":"nci-anetumab-pembrolizumab-mpm","name":"Pembrolizumab with or without anetumab ravtansine in mesothelin-positive pleural mesothelioma (NCI)","nct":"NCT03126630","phase":"1/2","status":"active"},{"id":"nct03785249","name":"Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1","nct":"NCT03785249","phase":"1/2","status":"active"},{"id":"checkmate-358","name":"CheckMate 358","nct":"NCT02488759","phase":"1/2","status":"completed"},{"id":"nct06079112","name":"9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer","nct":"NCT06079112","phase":"1/2","status":"recruiting"},{"id":"nct07563738","name":"A 2-part Phase 1/2 Open-label Trial on ODM-212","nct":"NCT07563738","phase":"1/2","status":"recruiting"},{"id":"nct05086692","name":"A Beta-only IL-2 ImmunoTherapY Study","nct":"NCT05086692","phase":"1/2","status":"recruiting"},{"id":"nct06305767","name":"A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)","nct":"NCT06305767","phase":"1/2","status":"active"},{"id":"nct04370587","name":"A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Adva","nct":"NCT04370587","phase":"1/2","status":"recruiting"},{"id":"nct06208410","name":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","nct":"NCT06208410","phase":"1/2","status":"recruiting"},{"id":"nct06428409","name":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","nct":"NCT06428409","phase":"1/2","status":"recruiting"},{"id":"nct06843447","name":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","nct":"NCT06843447","phase":"1/2","status":"recruiting"},{"id":"nct07255664","name":"A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC","nct":"NCT07255664","phase":"1/2","status":"recruiting"},{"id":"nct06413680","name":"A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Hav","nct":"NCT06413680","phase":"1/2","status":"recruiting"},{"id":"nct05584670","name":"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors","nct":"NCT05584670","phase":"1/2","status":"recruiting"},{"id":"nct06412198","name":"A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations","nct":"NCT06412198","phase":"1/2","status":"recruiting"},{"id":"nct07591597","name":"A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus F","nct":"NCT07591597","phase":"1/2","status":"planned"},{"id":"nct07632235","name":"A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma","nct":"NCT07632235","phase":"1/2","status":"planned"},{"id":"nct05180799","name":"A Phase 1/2 Study of BA3071 in Patients With Solid Tumors","nct":"NCT05180799","phase":"1/2","status":"active"},{"id":"nct06427941","name":"A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Sol","nct":"NCT06427941","phase":"1/2","status":"recruiting"},{"id":"nct06384807","name":"A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors","nct":"NCT06384807","phase":"1/2","status":"recruiting"},{"id":"nct07020221","name":"A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","nct":"NCT07020221","phase":"1/2","status":"recruiting"},{"id":"nct05585320","name":"A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors","nct":"NCT05585320","phase":"1/2","status":"active"},{"id":"nct05615974","name":"A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors","nct":"NCT05615974","phase":"1/2","status":"recruiting"},{"id":"nct06682780","name":"A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours","nct":"NCT06682780","phase":"1/2","status":"recruiting"},{"id":"nct06953323","name":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors","nct":"NCT06953323","phase":"1/2","status":"recruiting"},{"id":"nct05761223","name":"A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849","nct":"NCT05761223","phase":"1/2","status":"recruiting"},{"id":"nct07392736","name":"A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.","nct":"NCT07392736","phase":"1/2","status":"recruiting"},{"id":"nct05123482","name":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","nct":"NCT05123482","phase":"1/2","status":"recruiting"},{"id":"nct07040228","name":"A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer","nct":"NCT07040228","phase":"1/2","status":"recruiting"},{"id":"nct05846867","name":"A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer","nct":"NCT05846867","phase":"1/2","status":"active"},{"id":"nct06848699","name":"A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors","nct":"NCT06848699","phase":"1/2","status":"recruiting"},{"id":"nct07358585","name":"A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer","nct":"NCT07358585","phase":"1/2","status":"planned"},{"id":"nct07269158","name":"A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer","nct":"NCT07269158","phase":"1/2","status":"planned"},{"id":"nct06996782","name":"A Platform Study in Non-Small Cell Lung Cancer (NSCLC)","nct":"NCT06996782","phase":"1/2","status":"recruiting"},{"id":"nct06228326","name":"A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs","nct":"NCT06228326","phase":"1/2","status":"recruiting"},{"id":"nct05970497","name":"A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors","nct":"NCT05970497","phase":"1/2","status":"recruiting"},{"id":"nct05789082","name":"A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Par","nct":"NCT05789082","phase":"1/2","status":"recruiting"},{"id":"nct05320588","name":"A Study in Patients With Advanced Cancers","nct":"NCT05320588","phase":"1/2","status":"recruiting"},{"id":"nct07244705","name":"A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC","nct":"NCT07244705","phase":"1/2","status":"recruiting"},{"id":"nct07357220","name":"A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases","nct":"NCT07357220","phase":"1/2","status":"planned"},{"id":"nct06530251","name":"A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)","nct":"NCT06530251","phase":"1/2","status":"recruiting"},{"id":"nct07623356","name":"A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer","nct":"NCT07623356","phase":"1/2","status":"recruiting"},{"id":"nct06385080","name":"A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer","nct":"NCT06385080","phase":"1/2","status":"recruiting"},{"id":"nct03611868","name":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","nct":"NCT03611868","phase":"1/2","status":"active"},{"id":"nct07287995","name":"A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors","nct":"NCT07287995","phase":"1/2","status":"recruiting"},{"id":"nct07730021","name":"A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors","nct":"NCT07730021","phase":"1/2","status":"recruiting"},{"id":"nct04995523","name":"A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","nct":"NCT04995523","phase":"1/2","status":"active"},{"id":"nct03526835","name":"A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors","nct":"NCT03526835","phase":"1/2","status":"recruiting"},{"id":"nct04895709","name":"A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors","nct":"NCT04895709","phase":"1/2","status":"recruiting"},{"id":"nct05888831","name":"A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors","nct":"NCT05888831","phase":"1/2","status":"active"},{"id":"nct06697197","name":"A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors","nct":"NCT06697197","phase":"1/2","status":"recruiting"},{"id":"nct06521567","name":"A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer","nct":"NCT06521567","phase":"1/2","status":"active"},{"id":"nct05410145","name":"A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation","nct":"NCT05410145","phase":"1/2","status":"recruiting"},{"id":"nct07739966","name":"A Study of DS-3939a in Participants With Solid Tumors","nct":"NCT07739966","phase":"1/2","status":"planned"},{"id":"nct07559929","name":"A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.","nct":"NCT07559929","phase":"1/2","status":"recruiting"},{"id":"nct04078295","name":"A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor","nct":"NCT04078295","phase":"1/2","status":"active"},{"id":"nct05845814","name":"A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)","nct":"NCT05845814","phase":"1/2","status":"active"},{"id":"nct06483334","name":"A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)","nct":"NCT06483334","phase":"1/2","status":"active"},{"id":"nct06782555","name":"A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab","nct":"NCT06782555","phase":"1/2","status":"recruiting"},{"id":"nct06499350","name":"A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors","nct":"NCT06499350","phase":"1/2","status":"recruiting"},{"id":"nct05669430","name":"A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies","nct":"NCT05669430","phase":"1/2","status":"recruiting"},{"id":"nct05662397","name":"A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody","nct":"NCT05662397","phase":"1/2","status":"active"},{"id":"nct07535437","name":"A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer","nct":"NCT07535437","phase":"1/2","status":"recruiting"},{"id":"nct07535463","name":"A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer","nct":"NCT07535463","phase":"1/2","status":"recruiting"},{"id":"nct05518045","name":"A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors","nct":"NCT05518045","phase":"1/2","status":"active"},{"id":"nct06868199","name":"A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours","nct":"NCT06868199","phase":"1/2","status":"recruiting"},{"id":"nct06796907","name":"A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)","nct":"NCT06796907","phase":"1/2","status":"recruiting"},{"id":"nct05128487","name":"A Study of NDI 1150-101 in Patients With Solid Tumors","nct":"NCT05128487","phase":"1/2","status":"active"},{"id":"nct06090266","name":"A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents","nct":"NCT06090266","phase":"1/2","status":"recruiting"},{"id":"nct06362369","name":"A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy","nct":"NCT06362369","phase":"1/2","status":"recruiting"},{"id":"nct07266428","name":"A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors","nct":"NCT07266428","phase":"1/2","status":"recruiting"},{"id":"nct02332668","name":"A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)","nct":"NCT02332668","phase":"1/2","status":"recruiting"},{"id":"nct07302347","name":"A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)","nct":"NCT07302347","phase":"1/2","status":"recruiting"},{"id":"nct06038396","name":"A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors","nct":"NCT06038396","phase":"1/2","status":"recruiting"},{"id":"nct07602855","name":"A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)","nct":"NCT07602855","phase":"1/2","status":"recruiting"},{"id":"nct06879717","name":"A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients","nct":"NCT06879717","phase":"1/2","status":"active"},{"id":"nct06134375","name":"A Study of Tetrathiomolybdate (TM) Plus Capecitabine","nct":"NCT06134375","phase":"1/2","status":"recruiting"},{"id":"nct04481763","name":"A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast","nct":"NCT04481763","phase":"1/2","status":"recruiting"},{"id":"nct05423262","name":"A Study of TRK-950 in Patients With Advanced Solid Tumors","nct":"NCT05423262","phase":"1/2","status":"recruiting"},{"id":"nct05440708","name":"A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma","nct":"NCT05440708","phase":"1/2","status":"recruiting"},{"id":"nct06644768","name":"A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations","nct":"NCT06644768","phase":"1/2","status":"active"},{"id":"nct06117566","name":"A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors","nct":"NCT06117566","phase":"1/2","status":"recruiting"},{"id":"nct07208773","name":"A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors","nct":"NCT07208773","phase":"1/2","status":"recruiting"},{"id":"nct07258979","name":"A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.","nct":"NCT07258979","phase":"1/2","status":"recruiting"},{"id":"nct07169994","name":"A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","nct":"NCT07169994","phase":"1/2","status":"recruiting"},{"id":"nct07197827","name":"A Study of YL242 in Subjects With Advanced Solid Tumors","nct":"NCT07197827","phase":"1/2","status":"recruiting"},{"id":"nct04931654","name":"A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer","nct":"NCT04931654","phase":"1/2","status":"active"},{"id":"nct05944224","name":"A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.","nct":"NCT05944224","phase":"1/2","status":"recruiting"},{"id":"nct07749586","name":"A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors","nct":"NCT07749586","phase":"1/2","status":"recruiting"},{"id":"nct05319730","name":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","nct":"NCT05319730","phase":"1/2","status":"recruiting"},{"id":"nct06468358","name":"A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors","nct":"NCT06468358","phase":"1/2","status":"recruiting"},{"id":"nct05053880","name":"A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme","nct":"NCT05053880","phase":"1/2","status":"active"},{"id":"nct06116136","name":"A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.","nct":"NCT06116136","phase":"1/2","status":"active"},{"id":"nct05824975","name":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizu","nct":"NCT05824975","phase":"1/2","status":"recruiting"},{"id":"nct07223047","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance","nct":"NCT07223047","phase":"1/2","status":"recruiting"},{"id":"nct06618287","name":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors","nct":"NCT06618287","phase":"1/2","status":"recruiting"},{"id":"nct04590326","name":"A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamata","nct":"NCT04590326","phase":"1/2","status":"recruiting"},{"id":"nct05081609","name":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other","nct":"NCT05081609","phase":"1/2","status":"active"},{"id":"nct07115043","name":"A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors","nct":"NCT07115043","phase":"1/2","status":"recruiting"},{"id":"nct05661955","name":"A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants","nct":"NCT05661955","phase":"1/2","status":"active"},{"id":"nct05562830","name":"A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)","nct":"NCT05562830","phase":"1/2","status":"recruiting"},{"id":"nct07281976","name":"A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer","nct":"NCT07281976","phase":"1/2","status":"recruiting"},{"id":"nct04495296","name":"A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors","nct":"NCT04495296","phase":"1/2","status":"recruiting"},{"id":"nct04626635","name":"A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers","nct":"NCT04626635","phase":"1/2","status":"active"},{"id":"nct03972657","name":"A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metasta","nct":"NCT03972657","phase":"1/2","status":"recruiting"},{"id":"nct07158918","name":"ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors","nct":"NCT07158918","phase":"1/2","status":"recruiting"},{"id":"nct03897543","name":"ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma","nct":"NCT03897543","phase":"1/2","status":"recruiting"},{"id":"nct03686124","name":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","nct":"NCT03686124","phase":"1/2","status":"recruiting"},{"id":"nct06844422","name":"Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)","nct":"NCT06844422","phase":"1/2","status":"recruiting"},{"id":"nct05405595","name":"ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors","nct":"NCT05405595","phase":"1/2","status":"recruiting"},{"id":"nct05904379","name":"AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer","nct":"NCT05904379","phase":"1/2","status":"active"},{"id":"nct06646055","name":"AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer","nct":"NCT06646055","phase":"1/2","status":"active"},{"id":"nct07590531","name":"AMT-116 in Combination With AK112 in Patients With Lung Cancer","nct":"NCT07590531","phase":"1/2","status":"recruiting"},{"id":"nct07293754","name":"An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors","nct":"NCT07293754","phase":"1/2","status":"recruiting"},{"id":"nct04305795","name":"An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors","nct":"NCT04305795","phase":"1/2","status":"active"},{"id":"nct04785196","name":"APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors","nct":"NCT04785196","phase":"1/2","status":"recruiting"},{"id":"nct05632939","name":"ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.","nct":"NCT05632939","phase":"1/2","status":"active"},{"id":"nct06220318","name":"Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors","nct":"NCT06220318","phase":"1/2","status":"active"},{"id":"nct06137144","name":"AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.","nct":"NCT06137144","phase":"1/2","status":"recruiting"},{"id":"nct07469774","name":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","nct":"NCT07469774","phase":"1/2","status":"recruiting"},{"id":"nct04752826","name":"BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)","nct":"NCT04752826","phase":"1/2","status":"recruiting"},{"id":"nct06205706","name":"BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors","nct":"NCT06205706","phase":"1/2","status":"active"},{"id":"nct06530303","name":"Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer","nct":"NCT06530303","phase":"1/2","status":"recruiting"},{"id":"nct06572813","name":"Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer","nct":"NCT06572813","phase":"1/2","status":"recruiting"},{"id":"nct06825494","name":"Clinical Studies for the Treatment of Advanced Solid Tumors","nct":"NCT06825494","phase":"1/2","status":"recruiting"},{"id":"nct06821503","name":"Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C","nct":"NCT06821503","phase":"1/2","status":"recruiting"},{"id":"nct06400160","name":"Clinical Trial of TB511 in Advanced Solid Tumors","nct":"NCT06400160","phase":"1/2","status":"planned"},{"id":"nct06293651","name":"Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors","nct":"NCT06293651","phase":"1/2","status":"recruiting"},{"id":"nct07281716","name":"Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC","nct":"NCT07281716","phase":"1/2","status":"recruiting"},{"id":"nct07762703","name":"Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Incl","nct":"NCT07762703","phase":"1/2","status":"planned"},{"id":"nct06782932","name":"Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer","nct":"NCT06782932","phase":"1/2","status":"recruiting"},{"id":"nct06784648","name":"Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma","nct":"NCT06784648","phase":"1/2","status":"active"},{"id":"nct05431270","name":"Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy","nct":"NCT05431270","phase":"1/2","status":"recruiting"},{"id":"nct07410676","name":"EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors","nct":"NCT07410676","phase":"1/2","status":"recruiting"},{"id":"nct07025850","name":"Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer","nct":"NCT07025850","phase":"1/2","status":"planned"},{"id":"nct07262619","name":"EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Partic","nct":"NCT07262619","phase":"1/2","status":"recruiting"},{"id":"nct04205227","name":"ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors","nct":"NCT04205227","phase":"1/2","status":"active"},{"id":"nct07095868","name":"Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors","nct":"NCT07095868","phase":"1/2","status":"recruiting"},{"id":"nct05120596","name":"First in Human Study of T3P-Y058-739 (T3P)","nct":"NCT05120596","phase":"1/2","status":"recruiting"},{"id":"nct06877650","name":"First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors","nct":"NCT06877650","phase":"1/2","status":"recruiting"},{"id":"nct05438329","name":"First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors","nct":"NCT05438329","phase":"1/2","status":"active"},{"id":"nct04725474","name":"First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)","nct":"NCT04725474","phase":"1/2","status":"active"},{"id":"nct07355205","name":"First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer","nct":"NCT07355205","phase":"1/2","status":"recruiting"},{"id":"nct05749900","name":"First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)","nct":"NCT05749900","phase":"1/2","status":"recruiting"},{"id":"nct05919264","name":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","nct":"NCT05919264","phase":"1/2","status":"recruiting"},{"id":"nct05438459","name":"GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites","nct":"NCT05438459","phase":"1/2","status":"recruiting"},{"id":"nct04083599","name":"GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors","nct":"NCT04083599","phase":"1/2","status":"active"},{"id":"nct04977453","name":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","nct":"NCT04977453","phase":"1/2","status":"recruiting"},{"id":"nct04121455","name":"Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients","nct":"NCT04121455","phase":"1/2","status":"active"},{"id":"nct06265025","name":"GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors","nct":"NCT06265025","phase":"1/2","status":"recruiting"},{"id":"nct04652076","name":"GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab","nct":"NCT04652076","phase":"1/2","status":"active"},{"id":"nct05394103","name":"Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors","nct":"NCT05394103","phase":"1/2","status":"recruiting"},{"id":"nct05909436","name":"Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors","nct":"NCT05909436","phase":"1/2","status":"recruiting"},{"id":"nct06030258","name":"IN10018 Combination Therapy in Treatment-naïve ES-SCLC","nct":"NCT06030258","phase":"1/2","status":"recruiting"},{"id":"nct03491683","name":"INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)","nct":"NCT03491683","phase":"1/2","status":"active"},{"id":"nct07508761","name":"IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors","nct":"NCT07508761","phase":"1/2","status":"recruiting"},{"id":"nct05318469","name":"Ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer (Cedars-Sinai phase 1/2)","nct":"NCT05318469","phase":"1/2","status":"recruiting"},{"id":"nct06549946","name":"Ixovex-1 Single Agent and Combination Therapy","nct":"NCT06549946","phase":"1/2","status":"recruiting"},{"id":"nct07175389","name":"JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure","nct":"NCT07175389","phase":"1/2","status":"planned"},{"id":"nct04165070","name":"KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)","nct":"NCT04165070","phase":"1/2","status":"recruiting"},{"id":"nct07232602","name":"KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)","nct":"NCT07232602","phase":"1/2","status":"recruiting"},{"id":"nct07312422","name":"LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study","nct":"NCT07312422","phase":"1/2","status":"recruiting"},{"id":"nct04592653","name":"Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)","nct":"NCT04592653","phase":"1/2","status":"active"},{"id":"nct07561060","name":"Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy","nct":"NCT07561060","phase":"1/2","status":"recruiting"},{"id":"nct05655312","name":"MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma","nct":"NCT05655312","phase":"1/2","status":"recruiting"},{"id":"nct06761027","name":"mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer","nct":"NCT06761027","phase":"1/2","status":"recruiting"},{"id":"nct05329532","name":"Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer","nct":"NCT05329532","phase":"1/2","status":"recruiting"},{"id":"nct07479485","name":"MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)","nct":"NCT07479485","phase":"1/2","status":"recruiting"},{"id":"nct07639450","name":"N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors","nct":"NCT07639450","phase":"1/2","status":"recruiting"},{"id":"nct07277322","name":"Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases","nct":"NCT07277322","phase":"1/2","status":"recruiting"},{"id":"nct06384560","name":"Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)","nct":"NCT06384560","phase":"1/2","status":"recruiting"},{"id":"nct04041310","name":"Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors","nct":"NCT04041310","phase":"1/2","status":"active"},{"id":"nct05023486","name":"NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies","nct":"NCT05023486","phase":"1/2","status":"active"},{"id":"nct04616443","name":"OH2 Injection in Combination With HX008 for Melanoma.","nct":"NCT04616443","phase":"1/2","status":"recruiting"},{"id":"nct05271318","name":"Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) ","nct":"NCT05271318","phase":"1/2","status":"active"},{"id":"nct05438420","name":"Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors","nct":"NCT05438420","phase":"1/2","status":"active"},{"id":"nct04014530","name":"Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study","nct":"NCT04014530","phase":"1/2","status":"recruiting"},{"id":"nct06631079","name":"Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors","nct":"NCT06631079","phase":"1/2","status":"active"},{"id":"nct06631092","name":"Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer","nct":"NCT06631092","phase":"1/2","status":"recruiting"},{"id":"nct05269381","name":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","nct":"NCT05269381","phase":"1/2","status":"recruiting"},{"id":"nct06888674","name":"Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.","nct":"NCT06888674","phase":"1/2","status":"planned"},{"id":"nct06888648","name":"Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.","nct":"NCT06888648","phase":"1/2","status":"planned"},{"id":"nct03647163","name":"Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors","nct":"NCT03647163","phase":"1/2","status":"active"},{"id":"nct06249048","name":"Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab","nct":"NCT06249048","phase":"1/2","status":"recruiting"},{"id":"nct07751042","name":"Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab","nct":"NCT07751042","phase":"1/2","status":"recruiting"},{"id":"nct06795412","name":"Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors","nct":"NCT06795412","phase":"1/2","status":"recruiting"},{"id":"nct03907852","name":"Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer","nct":"NCT03907852","phase":"1/2","status":"active"},{"id":"nct04787042","name":"Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067","nct":"NCT04787042","phase":"1/2","status":"recruiting"},{"id":"nct06162572","name":"Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)","nct":"NCT06162572","phase":"1/2","status":"active"},{"id":"nct06144671","name":"Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors","nct":"NCT06144671","phase":"1/2","status":"recruiting"},{"id":"nct06088004","name":"Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors","nct":"NCT06088004","phase":"1/2","status":"recruiting"},{"id":"nct06149481","name":"Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Can","nct":"NCT06149481","phase":"1/2","status":"recruiting"},{"id":"nct05797168","name":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors","nct":"NCT05797168","phase":"1/2","status":"recruiting"},{"id":"nct07342725","name":"Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Met","nct":"NCT07342725","phase":"1/2","status":"planned"},{"id":"nct04126200","name":"Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple","nct":"NCT04126200","phase":"1/2","status":"active"},{"id":"nct06244992","name":"PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors","nct":"NCT06244992","phase":"1/2","status":"recruiting"},{"id":"nct05144698","name":"RAPA-201 Therapy of Solid Tumors","nct":"NCT05144698","phase":"1/2","status":"recruiting"},{"id":"nct07594106","name":"REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate ","nct":"NCT07594106","phase":"1/2","status":"recruiting"},{"id":"nct07219576","name":"Retifanlimab and Ruxolitinib In Solid Malignancies","nct":"NCT07219576","phase":"1/2","status":"recruiting"},{"id":"nct07468071","name":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other","nct":"NCT07468071","phase":"1/2","status":"recruiting"},{"id":"nct05101070","name":"S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors","nct":"NCT05101070","phase":"1/2","status":"recruiting"},{"id":"nct06963905","name":"Saci Nivo Rela for TNBC","nct":"NCT06963905","phase":"1/2","status":"recruiting"},{"id":"nct06238921","name":"Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases","nct":"NCT06238921","phase":"1/2","status":"recruiting"},{"id":"nct04262466","name":"Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors","nct":"NCT04262466","phase":"1/2","status":"active"},{"id":"nct06047379","name":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","nct":"NCT06047379","phase":"1/2","status":"recruiting"},{"id":"nct06016920","name":"Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma","nct":"NCT06016920","phase":"1/2","status":"recruiting"},{"id":"nct04521413","name":"Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies","nct":"NCT04521413","phase":"1/2","status":"active"},{"id":"nct04938817","name":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)","nct":"NCT04938817","phase":"1/2","status":"active"},{"id":"nct05732831","name":"Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors","nct":"NCT05732831","phase":"1/2","status":"recruiting"},{"id":"nct03970746","name":"Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC","nct":"NCT03970746","phase":"1/2","status":"active"},{"id":"nct06635785","name":"Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors","nct":"NCT06635785","phase":"1/2","status":"recruiting"},{"id":"nct04140526","name":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","nct":"NCT04140526","phase":"1/2","status":"active"},{"id":"nct05877430","name":"Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer","nct":"NCT05877430","phase":"1/2","status":"recruiting"},{"id":"nct05482893","name":"Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junct","nct":"NCT05482893","phase":"1/2","status":"recruiting"},{"id":"nct05501665","name":"Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer","nct":"NCT05501665","phase":"1/2","status":"recruiting"},{"id":"nct06975293","name":"STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas","nct":"NCT06975293","phase":"1/2","status":"recruiting"},{"id":"nct04130516","name":"Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab","nct":"NCT04130516","phase":"1/2","status":"active"},{"id":"nct04180371","name":"Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression","nct":"NCT04180371","phase":"1/2","status":"active"},{"id":"nct05163041","name":"Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression","nct":"NCT05163041","phase":"1/2","status":"active"},{"id":"nct04561362","name":"Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies","nct":"NCT04561362","phase":"1/2","status":"active"},{"id":"nct07287917","name":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors","nct":"NCT07287917","phase":"1/2","status":"recruiting"},{"id":"nct05267626","name":"Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Ca","nct":"NCT05267626","phase":"1/2","status":"recruiting"},{"id":"nct05651022","name":"Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors","nct":"NCT05651022","phase":"1/2","status":"active"},{"id":"nct04198766","name":"Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalen","nct":"NCT04198766","phase":"1/2","status":"recruiting"},{"id":"nct04699188","name":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","nct":"NCT04699188","phase":"1/2","status":"active"},{"id":"nct05620134","name":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","nct":"NCT05620134","phase":"1/2","status":"active"},{"id":"nct06942234","name":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer","nct":"NCT06942234","phase":"1/2","status":"recruiting"},{"id":"nct05933265","name":"Study of LP-184 in Patients With Advanced Solid Tumors","nct":"NCT05933265","phase":"1/2","status":"active"},{"id":"nct04956640","name":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","nct":"NCT04956640","phase":"1/2","status":"active"},{"id":"nct05533697","name":"Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors","nct":"NCT05533697","phase":"1/2","status":"recruiting"},{"id":"nct03476681","name":"Study of NEO-201 in Solid Tumors Expansion Cohorts","nct":"NCT03476681","phase":"1/2","status":"active"},{"id":"nct02861573","name":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","nct":"NCT02861573","phase":"1/2","status":"active"},{"id":"nct07644039","name":"Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies","nct":"NCT07644039","phase":"1/2","status":"recruiting"},{"id":"nct07397338","name":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors","nct":"NCT07397338","phase":"1/2","status":"recruiting"},{"id":"nct06162221","name":"Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC","nct":"NCT06162221","phase":"1/2","status":"recruiting"},{"id":"nct03564340","name":"Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent","nct":"NCT03564340","phase":"1/2","status":"recruiting"},{"id":"nct05838729","name":"Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer","nct":"NCT05838729","phase":"1/2","status":"recruiting"},{"id":"nct05887492","name":"Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors","nct":"NCT05887492","phase":"1/2","status":"active"},{"id":"nct05784688","name":"Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors","nct":"NCT05784688","phase":"1/2","status":"recruiting"},{"id":"nct06772623","name":"Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations","nct":"NCT06772623","phase":"1/2","status":"recruiting"},{"id":"nct04585035","name":"Study to Evaluate D-1553 in Subjects With Solid Tumors","nct":"NCT04585035","phase":"1/2","status":"active"},{"id":"nct04626479","name":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","nct":"NCT04626479","phase":"1/2","status":"active"},{"id":"nct04626518","name":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","nct":"NCT04626518","phase":"1/2","status":"active"},{"id":"nct06469944","name":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","nct":"NCT06469944","phase":"1/2","status":"recruiting"},{"id":"nct06780111","name":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","nct":"NCT06780111","phase":"1/2","status":"recruiting"},{"id":"nct07147231","name":"Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refracto","nct":"NCT07147231","phase":"1/2","status":"recruiting"},{"id":"nct04585750","name":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","nct":"NCT04585750","phase":"1/2","status":"recruiting"},{"id":"nct06532812","name":"TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer","nct":"NCT06532812","phase":"1/2","status":"recruiting"},{"id":"nct07681297","name":"Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Dis","nct":"NCT07681297","phase":"1/2","status":"planned"},{"id":"nct06456138","name":"Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC","nct":"NCT06456138","phase":"1/2","status":"planned"},{"id":"nct05187338","name":"Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors","nct":"NCT05187338","phase":"1/2","status":"recruiting"},{"id":"nct07276373","name":"Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies","nct":"NCT07276373","phase":"1/2","status":"recruiting"},{"id":"nct03556228","name":"VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma","nct":"NCT03556228","phase":"1/2","status":"recruiting"},{"id":"nct05205330","name":"Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers","nct":"NCT05205330","phase":"1/2","status":"active"},{"id":"mimic-01","name":"MIMic-01: healthy-donor FMT plus anti-PD-1, first-line melanoma","nct":"NCT03772899","phase":"1","status":"active"},{"id":"garnet","name":"GARNET","nct":"NCT02715284","phase":"1","status":"positive"},{"id":"nct02823405","name":"X4P-001 and Pembrolizumab in Patients With Advanced Melanoma","nct":"NCT02823405","phase":"1","status":"completed"}],"pathways":["immune-desert-exclusion","complement-in-cancer","caf-activation-desmoplasia","glutamine-metabolism","microbiome-tumour","mismatch-repair-msi","nutrient-competition-tme","oncogenic-viruses","pd1-checkpoint","t-cell-exhaustion","cancer-immunity-cycle","tumor-microenvironment"],"companies":["3sbio","agenus","akeso","arcus-biosciences","astrazeneca","beone","biocad","bms","cofactor-genomics","coherus","compass-therapeutics","compugen","elevar-therapeutics","eli-lilly","gsk","hutchmed","immvira-pharma","incyte","innovent","insight-molecular-diagnostics","hengrui","lepu-biopharma","macrogenics","merck","onc-ai","oncoc4","oncohost","ose-immunotherapeutics","pfizer","regeneron","henlius","shanghai-juncell-therapeutics","junshi","sino-biopharm","summit-therapeutics","takeda","xilio-therapeutics"],"keyPapers":["paper-checkmate-067-10-year-nejm-2025","paper-harmoni-2-lancet-2025","paper-cercek-nonoperative-management-mismatch-repair-deficient-tumours-nejm-2025","paper-zhu-population-specific-immunogenomics-gallbladder-cancer-mod-pathol-2025","paper-adriatic-nejm-2024","paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024","paper-ev-302-nejm-2024","paper-keynote-942-lancet-2024","paper-keynote-a18-os-lancet-2024","paper-keynote-a18-pfs-lancet-2024","paper-nadina-nejm-2024","paper-niche-2-nejm-2024","paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024","paper-swog-s1826-nivolumab-avd-nejm-2024","paper-keynote-042-tmb-mutations-ann-oncol-2023","paper-keynote-189-407-tmb-jtocrr-2023","paper-heymach-aegean-perioperative-durvalumab-nejm-2023","paper-provencio-nadim-ii-perioperative-nivolumab-stage-iii-nejm-2023","paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023","paper-ruby-nejm-2023","paper-ricciuti-tmb-pd-l1-levels-jama-oncol-2022","paper-cercek-dostarlimab-rectal-nejm-2022","paper-checkmate-816-nejm-2022","paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022","paper-spigel-pacific-five-year-survival-jco-2022","paper-keynote-522-nejm-2022","paper-relativity-047-nejm-2022","paper-felip-impower010-adjuvant-atezolizumab-lancet-2021","paper-asco-irae-guideline-jco-2021","paper-checkmate-649-lancet-2021","paper-clear-nejm-2021","paper-patil-gallbladder-immune-microenvironment-aimm-2021","paper-keynote-564-nejm-2021","paper-albrecht-pdl1-western-gallbladder-cancers-2021","paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020","paper-yamamoto-nature","paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020","paper-keynote-177-nejm-2020","paper-barroso-sousa-tmb-pten-ici-mtnbc-ccr-2020","paper-eng-imblaze370-atezolizumab-cobimetinib-colorectal-lancet-oncol-2019","paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019","paper-keynote-048-lancet-2019","paper-abida-msi-prostate-checkpoint-blockade-jama-oncol-2019","paper-keynote-189-nejm-2018","paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018","paper-checkmate-227-n-engl-j-med-2018","paper-ribas-wolchok-checkpoint-blockade-science-2018","paper-kras-nsclc-cancer-discov-2018","paper-tauriello-tgfbeta-immune-evasion-colorectal-nature-2018","paper-checkmate-026-first-line-nivolumab-nejm-2017","paper-le-mmr-deficiency-science-2017","paper-overman-checkmate-142-nivolumab-dmmr-colorectal-lancet-oncol-2017","paper-mlecnik-immunoscore-msi-colorectal-immunity-2016","paper-keynote-010-lancet-2016","paper-keynote-024-nejm-2016","paper-checkmate-017-nejm-2015","paper-checkmate-057-nejm-2015","paper-keynote-001-pembrolizumab-nsclc-nejm-2015","paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015","paper-le-mmr-deficiency-pd1-nejm-2015","paper-rizvi-mutational-landscape-pd1-science-2015","paper-tumeh-pd1-adaptive-immune-resistance-nature-2014","paper-chen-mellman-cancer-immunity-cycle-immunity-2013","paper-pardoll-immune-checkpoint-blockade-nrc-2012","paper-topalian-anti-pd1-nejm-2012","paper-iwai-pdl1-tumour-escape-pnas-2002"],"hotspots":[],"openQuestions":[{"id":"pd1-duration","question":"How long should checkpoint inhibitors be given: two years, one year, or until a ctDNA or imaging signal says stop?","stage":"clinical","actor":"payer","source":{"label":"CheckMate 067 ten-year follow-up, NEJM 2025","url":"https://doi.org/10.1056/NEJMoa2407417"}},{"id":"pd1-cold-tumours","question":"What actually turns an immune-desert tumour into one that responds to PD-1 blockade?","stage":"basic","actor":"research","source":{"label":"Topalian et al., NEJM 2012","url":"https://doi.org/10.1056/NEJMoa1200690"}},{"id":"pd1-neoadjuvant-standard","question":"For which cancers should neoadjuvant immunotherapy replace surgery-first, and can pathological response replace long-term endpoints?","stage":"clinical","actor":"clinic","source":{"label":"NADINA, NEJM 2024","url":"https://doi.org/10.1056/NEJMoa2402604"}}],"assays":[{"id":"pdl1-22c3","name":"PD-L1 IHC 22C3 pharmDx","cutoff":"TPS at least 1% or at least 50% (NSCLC); CPS at least 1 (head and neck, oesophageal, gastric); CPS at least 10 (TNBC, gastric first line); CPS at least 1 (cervical)"},{"id":"pdl1-28-8","name":"PD-L1 IHC 28-8 pharmDx","cutoff":"TC at least 1% (nivolumab plus ipilimumab, first-line NSCLC)"},{"id":"foundationone-cdx-panel","name":"FoundationOne CDx","cutoff":"Per companion claim: EGFR, ALK, BRAF V600, ERBB2 amplification, KRAS wild-type, BRCA1/2 and HRR genes, PIK3CA, MET exon 14, RET, FGFR2 fusions, IDH1, NTRK fusions; MSI-high; TMB at least 10 mutations per megabase"},{"id":"mmr-ventana","name":"VENTANA MMR RxDx Panel","cutoff":"Loss of nuclear expression of any mismatch-repair protein in tumour cells (dostarlimab, endometrial cancer)"},{"id":"msi-pcr","name":"MSI by PCR (Promega MSI Analysis System and equivalents)","cutoff":"Instability at two or more of five markers (MSI-high); NGS panels report MSI from hundreds of loci"},{"id":"tmb-panel","name":"Tumour mutational burden (FoundationOne CDx and equivalents)","cutoff":"At least 10 mutations per megabase (pembrolizumab, tumour-agnostic, KEYNOTE-158)"}],"resistance":[{"class":"pd1-blockade","mechanism":"Loss of antigen presentation (B2M, HLA, JAK1/2)","category":"immune-evasion"},{"class":"pd1-blockade","mechanism":"Immune-desert / excluded tumours","category":"immune-evasion"},{"class":"pd1-blockade","mechanism":"Alternative checkpoints (LAG-3, TIM-3, TIGIT)","category":"bypass"},{"class":"pd1-blockade","mechanism":"Immunosuppressive myeloid cells and VEGF","category":"immune-evasion"},{"class":"pd1-blockade","mechanism":"Loss of neoantigens / low TMB","category":"antigen"},{"class":"pd1-hodgkin","mechanism":"Loss of MHC class II on the Reed-Sternberg cell","category":"immune-evasion"},{"class":"pd1-hodgkin","mechanism":"CIITA rearrangement","category":"immune-evasion"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}